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Abstract
Aflatoxin B1 (AFB1) is a food contaminant with detrimental impact on human and animal
health. Intervention approaches focus on pre- and post-harvest measures to reduce AFB1
levels in crops or on the individual level to modulate bioactivation and excretion of AFB1
or reduce its bioavailability. Probiotic bacteria have been identified as a potential means to
reduce availability of AFB1 as well as other food contaminants. In this study we used both
in vitro and in vivo approaches to study the interplay between probiotic bacteria and AFB1
in the intestinal environment. Initially, the binding ability of several probiotics was
explored in vitro. Intestinal mucus was found to compete with AFB1 binding sites on the
surface of bacteria. This should be taken into consideration when choosing a probiotic for
AFB1 binding, as was also evident from our studies in the duodenal loop of chicks, where
different probiotics with similar binding capacity in vitro, had different effects on AFB1
absorption from the intestine. As a subsequent step, rats were dosed orally with AFB1 and
probiotics and fecal excretion of AFB1 was significantly but transiently increased by
probiotic dosing, possibly reflecting a reduction in absorption of AFB1 from the intestinal
lumen. Furthermore, AFB1 induced hepatotoxicity was slightly reduced and weight loss
was alleviated in rats dosed with probiotics. To study whether the AFB1 binding by the
probiotic bacteria has an effect on its transport and toxicity to the intestinal tissue, Caco-2
cells were incubated with AFB1 and direct toxic effects on epithelial integrity and
genotoxic effects were observed in the presence and absence of the bacteria. When the
probiotic bacteria were added, AFB1 toxicity could be reduced. In conclusion, these
studies clearly show the protective effects of probiotic bacteria against AFB1 induced
intestinal and systemic toxicity via binding AFB1 and reducing its transport in different
test systems.
National Library of Medicine Classification: QW 125.5.P7, QW 142.5.A8, QW 630, WI
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1 Introduction
Food is the fuel of life, and we are all concerned about the quality and safety of our
food. Harmful components in plant derived foods can be either produced by the plant
itself, or are contaminants deriving from manmade sources or from microorganisms.
Among these microorganisms, toxin producing fungi are ubiquitous in the environment
and can invade our crops and produce toxic secondary metabolites known as mycotoxins.
Worldwide, millions of tons of crops are destroyed every year due to fungal growth and
spoilage, to reduce human exposure to mycotoxins. Technologies are available to
minimize fungal growth and contamination during harvest, processing and storing of
crops, but these methods are only available in developed countries, resulting in a divided
prevalence of mycotoxin exposure. Low level mycotoxin exposure occurs in parts of the
world where food is available in higher quality and variety, whereas high level exposure
causes acute disease which may result in death and is prevalent in areas where populations
depend on a single staple food commodity.
Aflatoxins are a group of mycotoxins, commonly contaminating maize and
groundnuts, and are categorized as class 1 A human carcinogens by the International
Agency for Research on Cancer (IARC, 2002). Low level chronic aflatoxin exposure is
linked to the development of “occult” conditions such as impaired growth and immune
function and chronic diseases such as liver cancer in areas where the aflatoxin producing
Aspergillus fungi is prevalent. It is therefore of major interest, to prevent formation of
aflatoxins in the first place, or to reduce its bioavailability from foods to prevent harmful
effects.
Microorganisms, especially bacteria, have been studied for their potential to either
degrade mycotoxins or reduce their bioavailability. Among these bacteria, probiotic lactic
acid bacteria have been identified as a safe means to reduce availability of aflatoxins in
vitro. Furthermore, probiotic bacteria exert a number of other beneficial health effects,
which make them even more suitable additives to food and feed.
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In this study, the potential of probiotic bacteria to bind aflatoxin to their surface and
thereafter reduce aflatoxin uptake and harmful effects was investigated. Both in vitro and
in vivo experiments were conducted to mimic conditions inside the intestinal tract to
evaluate the potential of probiotic bacteria to interfere with processes of absorption and
metabolism of AFB1.
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2 Review of the literature
2.1 Intestine
The role of the intestinal tract in digestion and absorption of nutrients and xenobiotics
is of fundamental importance in the research fields of nutrition, pharmacology and
toxicology. Absorption of chemicals (nutrients, xenobiotics) is greatly influenced by two
factors, firstly the intestinal content (gut lumen) with its diverse and complex bacterial
ecosystem together with the mixture of ingested material (i.e. food)  and digestive juices
and secondly the intestinal epithelium (gut wall) with its absorptive and metabolic capacity
(Ilett et al., 1990).
The intestinal microbiota form a symbiotic interaction with the host, and provide a
range of metabolic activities, which can affect the host in a beneficial or harmful way
(Schiffrin and Blum, 2002). The secretion of digestive juices, mucus and bicarbonate
determine the organism’s ability to digest and absorb the ingested materials. The quality of
ingested material will also affect its digestibility and its effect on the intestinal mucosa.
Many food contaminants and drugs are known to damage the intestinal epithelia, and
therefore affect the absorptive capacity and well being.
2.1.1 Brief description of anatomical and physiological features
The intestinal mucosa is composed of three layers, the muscularis mucosa (the deepest
layer), the lamina propria (the in-between layer of connective tissue) and the mucosal
epithelium, a continuous sheet of epithelial cells, one cell thick, lining villi and crypts
(Henry, 1982). The mucularis mucosa consists of two sublayers of longitudinal and
circular muscle and is involved in the contractile processes of peristalsis in the intestinal
tract. The lamina propria, also referred to as submucosa, is composed of extracellular
matrix and provides stability to the epithelial cell layer. Embedded are lymph and blood
vessels, smooth muscle cells, nerves and a variety of immune competent cells such as
plasma cells, lymphocytes and macrophages, all part of the gut associated lymphoid tissue
(GALT) (Henry, 1982). The lamina propria also expands into villi, supporting the folds of
18
the intestinal epithelium structurally, which are most abundant in the upper intestinal tract.
The composition is illustrated in Figure 1.
Figure 1: Schematic picture of the microanatomy of the digestive tube. Adapted from
http://www.adam.com
The most important kinds of epithelial cells tightly lining the surface of the intestinal
tract are absorptive enterocytes and secretive goblet cells on the villi and undifferentiated,
proliferative cells in the crypts. The absorptive cells (enterocytes) are tall columnar cells of
polar shape, with microvilli expanding from their apical surface into the intestinal lumen
(Doherty and Charman, 2002). Goblet cells lie scattered in between enterocytes, and are
responsible for secretion of mucus glycoproteins, which form a protective mucus layer all
throughout the intestinal tract (Henry, 1982).
2.1.2 Intestinal absorption and metabolism of xenobiotics
The surface of the proximal intestinal tract is the optimal site of absorption of
chemicals. Two major modes of absorption are described for the uptake of chemicals from
the lumen into the systemic circulation: (a) passive permeability down a concentration
gradient (which is most common for xenobiotic absorption) or (b) carrier-mediated uptake
which can happen either facilitatively (not energy requiring)  or actively (energy
consuming) (Doherty and Charman, 2002). A third mode of absorption is paracellular
passive permeability (c). The carrier or transporter molecules within the intestinal
membrane can either be absorption proteins, often specific for the uptake of nutrients, or
efflux proteins (d) (such as P-glycoprotein or multi drug resistance protein (MRP), both
members of the ATP-binding cassette superfamily), important for pumping xenobiotics
Villus
Submucosa
Solitary lymphatic follicle
Crypt
Circular muscle
Longitudinal muscle
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(drugs, toxins) out of the enterocytes back into the intestinal lumen (Doherty and
Charman, 2002). These absorption modes are illustrated in Figure 2.
Figure 2: Different pathways for intestinal absorption of a compound. The intestinal
absorption of a compound can occur via several pathways: (a) transcellular passive
permeability; (b) carrier-mediated transport; and (c) paracellular passive permeability.
However, there are also mechanisms that can prevent absorption: (d) intestinal absorption
can be limited by P-gp, which is an ATP-dependent efflux transporter; and (e) metabolic
enzymes in the cells might metabolize the compound. From (Balimane and Chong, 2005).
 Once a chemical has entered the enterocytes, it will be subject to metabolism by the
enzymes present (e). For xenobiotics, this basically means phase I and phase II reactions,
both aiming at making components more water soluble and easier to excrete (Vermeulen,
1996). One of the most prominent phase I enzyme families is the cytochrome P450
enzymes (CYPs), a superfamily of membrane associated haemoproteins, concentrated in
the endoplasmatic reticulum of liver and intestinal cells (Ding and Kaminsky, 2003).
Among these, CYP 3A4 is the most important of all human drug metabolizing enzymes,
and plays a major role in the intestine, since it is strategically located in high
concentrations at the tip of the villus, and is always positioned in close vicinity to the P-
glycoprotein within the enterocytes (Lindell et al., 2003). It also plays a role in
bioactivation of xenobiotics such as aflatoxin, which will be discussed in detail later.
Furthermore, phase II conjugation enzymes are also found in enterocytes in the gut
epithelium (Doherty and Charman, 2002).
2.1.3 Models to study intestinal metabolism and absorption of chemicals
The intestinal tract has long been studied for its metabolic and absorptive capacity for
nutrients and other chemicals. Various models in vitro (in the test tube), ex vivo (with live
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tissue separated from the animal) and in vivo (in the live animal) have been developed, all
aiming at improving the proximity of the assay to the “real” situation inside the gut. These
methods will be briefly described here.
In vitro methods
Processes inside the intestinal lumen contain digestion reactions of nutrients with
secreted digestive enzymes, and reactions of nutrients and chemicals with microbiota,
colonizing the intestinal tract. In vitro studies allow to mimic the intestinal milieu of the
upper intestinal tract by subsequently adding digestive agents such as mucus, digestive
enzymes, different pHs (using HCl and bicarbonate) and bile acids into reaction chambers
(Versantvoort et al., 2005; Brandon et al., 2006). The lower intestinal tract is modeled by
inoculating foods with intestinal microbiota (Aura et al., 2006) in reaction systems called
“simulator of the human intestinal microbial ecosystem” (SHIME).
Both in vitro setups are widely used for survival studies of probiotics (Ouwehand et
al., 2001). Furthermore, studies on bioaccessibility (i.e. the fraction of the contaminant that
is released from the food) of harmful food components have been performed in vitro
(Versantvoort et al., 2005). The major disadvantage of this type of study is the lack of
absorptive capacity, but recently a combined in vitro digestion/Caco-2 cell culture system
was used to study iron bioavailability (i.e. the fraction of an administered dose that reaches
the systemic circulation) (Yun et al., 2004).
To study the intestinal metabolism of test compounds, the simplest approach is to
separate subcellular fractions of enterocytes (cytosol, microsomes, brushborder fragments,
nuclei), usually by a series of centrifugation steps, and then study enzyme activities of
these fractions (Peters, 1982; Ilett et al., 1990). Different materials, such as animal tissues,
human biopsy samples or cell lines can be used for this approach, and it has allowed the
elucidation of many enzymatic pathways in enterocytes and other cell types.
However, absorption can not be studied in this setup. Primary cell culture (where
proliferative cells are removed from an animal and cultured for several days) and cell lines
(often immortalized cells, provided by tissue culture collections) are widely used today,
with Caco-2 cells being most extensively characterized (Balimane and Chong, 2005).
Caco-2 cells are derived from human colon carcinoma tissue and differentiate
spontaneously into small intestinal epithelia like enterocytes. This feature makes them a
strong tool for drug absorption studies, and many clones have been described, which
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express different enzyme systems and produce intestinal mucus (Balimane and Chong,
2005).
Tissue pieces or whole organs can be removed from the animal, and also used in
culture for a limited amount of time, to allow the study of physiological tissues. Tissue
slices and everted intestinal sacs have been used to study transport of nutrients for a long
time, and still have some relevance to date in studies of xenobiotics absorption (Hugon et
al., 1982; Carrillo et al., 1985; Ilett et al., 1990; Ramos and Hernandez, 1996; Iida et al.,
2006; Ohta et al., 2006).
In situ/ex vivo methods
In situ perfused gut loops and ex vivo intestinal loops have been used, where the tissue
is not removed from the animal, but rather stays in place. Different compartments of the
intestine can be separated by ligatures and absorption of chemicals can be studied (Davies,
1980; Bertholon et al., 2006). This kind of study allows testing absorption of components
in the small intestine, since the blood flow and physiological conditions inside the loop
stay intact.
In vivo methods
Physiological models use live animals, dosed with the xenobiotics of interest,  and the
concentration of the chemical or its metabolites can be determined in the systemic
circulation or the target tissue (Ilett et al., 1990). These studies give information about
bioavailability, rate of absorption and clearance, for example by studying the xenobiotic or
its metabolites in plasma samples. From these measurements, area under the curve values
from concentration/time diagrams can be calculated and different xenobiotic preparations
or routes of exposure can be compared (Ilett et al., 1990; Hsieh and Wong, 1994).
Furthermore, the adverse effects of toxins, systemic or specific organ damage, can be used
as markers for internal dose of the compound (e.g. liver damage, body weight of rats).
Given the long list of experimental approaches available to study intestinal absorption
and metabolism, the choice of the suitable technique is crucial. A research question has to
be clearly defined in order to evaluate, which technique is able to answer it. Clearly in vivo
animal experiments have many advantages over in vitro techniques, but ethical issues must
be considered when choosing. Current regulations on animal experimentation are based on
the principle of the three Rs: Reduction, Replacement and Refinement, which have
become the basis for “humane”, ethical animal research (Kolar, 2006). Replacing animal
22
O
OO OCH3
O O
O
OO OCH3
O O
OH
O
OO OCH3
O O
OH
O
OO OCH3
O O
O
OO OCH3
O O
O
OO
OO OCH3
O O
AFB1 AFM1
AFM2
AFG1
AFG2AFB2
experiments with other suitable techniques and optimizing animal studies with number of
animals and procedures used are most important points to be considered.
Nevertheless, animal experimentation has played a fundamental role in the research
field of toxicology, and has provided a vast knowledge about the health risks that
xenobiotics such as aflatoxins can pose for animals and humans.
2.2 Aflatoxins
Contamination of feed with Aspergillus flavus was first discovered after an outbreak
of sudden death among several hundred thousand ducklings and turkeys in the year 1960
and was later named “Turkey X Disease” (Blount, 1961). This finding led to the isolation
of a fluorescent compound referred to as aflatoxin as an abbreviation of “Aspergillus
flavus toxin” (Nesbit et al., 1962). The chemical structures of the six major dietary
aflatoxins are shown in Figure 3.
Figure 3: Chemical structures of major dietary aflatoxins namely aflatoxin B1, G1 and M1
with the double bonds in 8-9 positions and aflatoxins B2, G2 and M2 without the double
bond.
Chemically, aflatoxins are a group of difuranocoumarin derivatives that show
fluorescence under ultraviolet light. According to the color of the fluorescence the
aflatoxins are grouped into aflatoxin B1 and B2 (AFB1, AFB2) for blue, and G1 and G2
(AFG1, AFG2) for green, where subscripts refer to the chromatographic mobility.
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Aflatoxin M1 and M2 (AFM1, AFM2), known as milk-aflatoxins, are metabolites of AFB1
and AFB2 (Carnaghan et al., 1963).
AFB1 is the most toxic and most prevalent compound, followed by G1, B2 and G2 with
decreasing toxicity (Busby, 1984). AFM1 is frequently detected in dairy products, and its
toxicity is comparable to AFB1 (Busby, 1984). Aflatoxins can be produced by the four
toxic species of Asperagillus: A. flavus, A. flavus ssp. parasiticus, A. nomius and A.
pseudotamarii (Pitt, 2000; CAST, 2003) as secondary metabolites. Occurrence of these
molds and therefore aflatoxin contamination is limited to warm and humid climates and
most frequently detected in Sub-Saharan Africa and Southeast Asia. Food commodities
most frequently detected with aflatoxins are corn and corn products, peanuts, dried fruits
and dairy products (AFM1) (IARC, 1993). Daily human aflatoxin exposure varies between
countries and was estimated between 4-184 ng/kg body weight in various African
countries, 12-2027 ng/kg body weight in Southern China and 7-53 ng/kg body weight in
Thailand, as compared to <3 ng/kg body weight in the USA (Hall and Wild, 1994;
Williams et al., 2004). Maximum legal concentrations of total aflatoxins in foodstuffs are
set in many countries, the EU for example has set  4 ?g/kg food intended for direct human
consumption (de Koe, 1999). The further part of this literature review will focus on
aflatoxin B1 and its metabolites.
2.2.1 Toxicokinetics of aflatoxin B1
Route of exposure and absorption
AFB1 is a common food contaminant and exposure in humans and animals mainly
occurs trough the oral route. However, inhalation of contaminated grain dust was found to
be a major source of AFB1 exposure in people in special occupational settings (Cullen and
Newberne, 1994). Following ingestion, aflatoxin B1 is efficiently absorbed in the intestinal
tract, and the duodenum was found as the major site of absorption (Hsieh and Wong,
1994). Since AFB1 is a low molecular weight compound, passive diffusion into the
enterocyte was suggested as a mechanism of absorption (Kumagai, 1989; Hsieh and
Wong, 1994; Fernandez et al., 1997). These findings are further supported by a study
showing that AFB1 transport through a Caco-2 monolayer occurs at similar rates from
apical to basolateral side and vice versa  (Mata et al., 2004). This study suggests that no
efflux pumps or transporters are involved in AFB1 absorption or extrusion, although
another study (Loe et al., 1997) found a multidrug resistence protein that extruded
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aflatoxin-glutathione conjugate (AFB1-GSH) and low levels of unmetabolized AFB1 from
cells. Following respiratory exposure, AFB1 might appear in the blood more rapidly than
after oral exposure, but after 4 hours the plasma concentration-time plots did not differ
between the two routes of exposure (Coulombe and Sharma, 1985). Following absorption,
first pass metabolism of AFB1 already occurs in the intestinal and respiratory epithelium,
although the impact of these metabolic sites is still to be evaluated. From the site of
absorption, AFB1 enters the blood stream and is transported to the liver, the major site of
metabolism.
Metabolism
Metabolism of several dietary aflatoxins follows similar pathways, but with respect to
occurrence and toxic effect, this review focuses on aflatoxin B1. Metabolism of
xenobiotics including AFB1 can be divided into three phases, bioactivation (phase I),
conjugation (phase II) and deconjugation (phase III), all of which can occur directly at the
site of absorption, in the blood, after entering the liver as the main metabolizing organ, or
in several extra-hepatic tissues (Vermeulen, 1996). Aflatoxin B1 itself is not a potent toxin,
and phase I bioactivation is needed to exert toxic effects (Massey et al., 1995). Phase I
reactions are mainly oxidation of AFB1 to hydroxylated metabolites such as aflatoxin M1,
aflatoxin Q1 and aflatoxin P1 and to the highly reactive AFB1-8,9-epoxide (Eaton and
Gallagher, 1994; Eaton et al., 1994). This epoxide can occur in two isomers, the endo- and
the exo-form, but only the exo-isomer is of relevance in terms of toxicity and
carcinogenicity (Massey et al., 1995). The formed epoxide is highly unstable, and will
readily bind to biological nucleophils such as nucleic acids (alkylation) to form stable
adducts with RNA and DNA (Eaton et al., 1994; Smela et al., 2001). Covalent binding of
AFB1-8,9-epoxide to DNA is known to induce point mutations and DNA strand breaks,
and is linked to the carcinogenic effects of AFB1 exposure. In the presence of water, the
epoxide will be rapidly and non-enzymatically hydrolyzed to AFB1-8,9-dihydrodiole,
which is able to form Schiff bases with primary amino groups in lysine residues (Sabbioni
et al., 1987). One of the proteins, readily available for AFB1 adduct formation is serum
albumin, forming a stable adduct persisting in the blood circulation of rats for several days
(Sabbioni et al., 1987) and humans for several weeks. Therefore, levels of AFB1-albumin
or AFB1-lysin after proteolytic digestion are widely used as biomarkers of AFB1 exposure.
The mechanism of diol formation and protein adduction is most likely involved in the
acute toxic effects of aflatoxin (Eaton et al., 1994). Thus it is possible that aflatoxin could
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cause gross damage to cells at the intestinal interface, reducing nutrient uptake, or may
specifically target important functional sites such as nutrient transporters or tight junctions.
Major metabolic pathways are summarized in Figure 4.
Figure 4. Major metabolic pathways of AFB1 (Eaton et al. 1994, Massey et al. 1995,
McLean and Dutton 1995, Ueng et al. 1995, Guengerich 2001, Van Vleet et al. 2001).
Cytochrome P450 enzymes (CYPs) are known to play the major role in oxidation of
AFB1 to the reactive epoxide in many tissues, although lipoxygenases and prostaglandin H
synthase, in the presence of arachidonic acid (Battista and Marnett, 1985; Massey et al.,
1995), have been shown to have the capacity, in humans, to catalyse this oxidation in
extra-hepatic organs.
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CYP enzymes are a family of haemoproteins with the capacity for monooxygenase
enzymic metabolism of toxic hydrocarbons. The reduced form of nicotinamide adenine
dinucleotide phosphate (NADPH) is required as a cofactor and oxygen is used as
a substrate (Vermeulen, 1996). Although predominantly expressed within the liver, CYPs
are additionally expressed extra-hepatically within most tissues and especially in the
respiratory and intestinal tract, thereby providing intestinal cells in vivo with the capacity
to bioactivate aflatoxin (Larsson and Tjalve, 1995).
CYP nomenclature uses Arabic numbers for the family and letters for the subfamily of
enzymes. Of the CYP enzymes, CYP 1A2 and the CYP 3A family play a fundamental role
in aflatoxin bioactivation (Massey et al., 1995; Gallagher et al., 1996). CYP 3A4 has the
capacity to metabolize AFB1 to form the AFB1-exo-8,9- epoxide, whilst the majority of its
enzymatic action hydroxylates AFB1 to aflatoxin Q1 (AFQ1), a less toxic metabolite (Ueng
et al., 1995). The formation of AFQ1 and AFB1-exo-8,9-epoxide at a ratio of 10:1 was
observed in CYP 3A4 complementary DNA (cDNA)-expressing lymphoblastoid
microsomal preparations (Gallagher et al., 1996). Conversely, CYP 1A2 metabolism forms
the hydroxylated aflatoxin M1 (AFM1) and the AFB1 epoxide in a ratio 1:2.5 in the same
system. However, CYP 1A2 was found to produce a mixture of both the endo- and exo-
isomer of the epoxide (Guengerich et al., 1996). A recent study suggests that CYP 3A4
contributes to the total hepatic AFB1-epoxide formation with 79% in human liver
microsomes, and that CYP 3A5, a polymorphic variant of the gene, also has a significant
role in high expressers (Kamdem et al., 2006). The degree of contribution may also
depend on AFB1 exposure levels with low levels favoring CYP 1A2 (Hengstler et al.,
1999).
Hydroxylated AFB1 metabolites (AFQ1, AFM1, AFP1) are less toxic because they are
much poorer substrates for epoxidation. (Cullen and Newberne, 1994). However, AFM1
has also been shown to exert direct toxic properties without metabolic activation, in
contrast to AFB1 (Neal et al., 1998) Reduction of the 1-keto group of AFB1 produces the
metabolite aflatoxicol (AFL) (Busby, 1984). This reduction is catalyzed by a cytosolic
reductase and AFL can be readily oxidized back to AFB1. AFL is not considered a
significant AFB1 detoxification product since it has been shown to have comparable
carcinogenicity and 70% the mutagenicity of AFB1 (Eaton et al., 1994) and can readily be
oxidized back to AFB1. It was therefore suggested to be a “reservoir” for AFB1 in vivo
(Hsieh and Wong, 1994).
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Phase II metabolism includes conjugation of phase I metabolites with glutathione or
glucuronic acid and is considered detoxification to enhance water solubility and excretion
(Massey et al., 1995). Epoxide can be conjugated with glutathione with the help of
glutathione-S-transferase (Degen and Neumann, 1978; Cullen and Newberne, 1994), an
enzyme essential in the reduction and prevention of AFB1 induced carcinogenicity.
Conjugates of epoxide and hydroxylated AFB1 metabolites are readily excreted via the bile
into the intestinal tract, where they might be subject to bacterial deconjugation as phase III
reaction. The metabolism and toxicity of AFB1 have been studied in human cellular
systems derived from liver (Knasmüller et al., 2004) or respiratory tract (Van Vleet et al.,
2001), but the impact of the intestinal metabolism is still to be investigated.
Excretion
The major route of excretion of AFB1 and its metabolites is the biliary pathway,
followed by the urinary pathway. In lactating animals, AFM1 and other metabolites are
excreted in the milk.
Coulombe and Sharma (1985) found the cumulative excretion of AFB1 radioactivity
over 23 days after a single dose (0.6 mg/kg body weight) to be 55% in feces and 15 % in
urine of rats. In rat bile, AFB1-GSH conjugate was identified as the major metabolite,
followed by AFP1-glucuronide (Hsieh and Wong, 1994). Reabsorption of bile-borne
metabolites only occurs at high dose levels (0.5-2.5 mg/kg body weight) (Degen and
Neumann, 1978), when chloroform extractable, absorbable metabolites were detected, but
not at low dose levels (Hsieh and Wong, 1994). Deconjugation of conjugated biliary AFB1
metabolites by intestinal microbiota may occur, but has not been studied extensively. In
lambs, AFM1 was detected as the only aflatoxin metabolite found in feces besides dietary
AFB1 and AFG2 (Fernandez et al., 1997), and in humans, AFQ1 and AFM1 were detected
from fecal samples of AFB1 exposed subjects (Mykkänen et al., 2005). Fecal excretion of
AFB1 and metabolites has mainly been assessed either via analyzing contents of bile, or by
measuring total fecal radioactivity following administration of radioactive AFB1. Neither
method gives definite information about the presence of unabsorbed AFB1 in the fecal
material. Given the efficiency of the intestinal epithelium to absorb AFB1, detection of
unabsorbed AFB1 is unlikely, but may occur at high dose levels.
In urine, the three major metabolites found in rat and human are AFM1, AFB1-N7-
guanine, the degradation product of hepatic AFB1-DNA adducts, and AFP1. The
hydroxylated AFB1 metabolites, including AFM1, AFQ1 and the demethylation metabolite
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aflatoxin P1 (AFP1), are excreted from the body in urine (Groopman et al., 1985; Hsieh
and Wong, 1994). Recently, a 10-fold higher level of AFQ1 has been found in human urine
compared to that of AFM1 (Mykkänen et al., 2005).
2.2.2 Toxicity and carcinogenicity of aflatoxins
Effects on humans
A recent outbreak of aflatoxicosis in Kenya has resulted in 125 deaths among 317
cases of poisoning (CDC, 2004). The case fatality rate was 39%, caused by levels of AFB1
in home-grown maize reaching up to 8 mg/kg maize. Several previous outbreaks of
aflatoxicosis have occurred in Africa and India, mostly in adults with poor nutritional
status and maize as staple food (IARC, 1993). The clinical picture indicated acute toxic
liver injury manifested as jaundice with a mortality rate of 10-60% (Peraica et al., 1999).
From these findings it can be concluded that the acute lethal dose for adult humans is in
the order of 10-20 mg (Pitt, 2000).
In humans, numerous studies have linked the incidence of primary hepatocellular
carcinoma with the intake of aflatoxins, leading to the classification of AFB1 as class 1
human carcinogen by the IARC (IARC, 1993). Areas of high incidence of liver cancer
such as China, Taiwan and sub-Saharan Africa, also have the highest prevalence for
aflatoxin exposure and hepatitis B virus, leading to the theory that these two
hepatocarcinogens act synergistically (Kew, 2003).
Besides the carcinogenic effects, aflatoxins are also implicated with
immunomodulatory effects and the occurrence of infectious disease as well as with growth
faltering effects in children (Gong et al., 2002; Williams et al., 2004). Epidemiological
studies show geographical similarities in the occurrence of aflatoxins in food and
kwashiorkor (Peraica et al., 1999).
Effects on animals
Toxic and especially carcinogenic effects of aflatoxins have been reported in several
different animals, but susceptibility to these toxins varies greatly with sex, age, species and
strain within a species (Busby, 1984; CAST, 2003). Experimentally verified LD50 values
(lethal dose for 50% of animals) for rats for example, vary between 0.75 and 17.9 mg/kg
body weight between animals of different age, sex or strain (Busby, 1984). Numerous
animal studies have shown that the liver is the main target organ and therefore the main
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symptoms of aflatoxin exposure in domestic and laboratory animals are hepatic injuries
(Busby, 1984; Robens and Richard, 1992; IARC, 1993).
Table 1: Acute toxicity of dietary aflatoxins in various species.
Aflatoxin Species (all male) Age/weight Route of
exposure
LD50
mg/kg body weight
AFB1 Chicken 21 days p.o.a 18
Mouse (CFW swiss) 30 days (20g) p.o. 10.2
Rat (Porton-Wistar) 100-150g p.o. 7.2
Rat (Fischer) 200g p.o. 1.16
AFG1 Rat (Fischer) 200g p.o. 1.5-2.0
AFB2 Rat (Fischer) 200g p.o. >100x of AFB1
AFG2 Rat (Fischer) 200g p.o. >100x of AFB1
AFB1 Duck (Pekin) 50g i.p.b 0.73
AFG1 Duck (Pekin) 50g i.p. 1.76
AFB2 Duck (Pekin) 50g i.p. 1.18
AFG2 Duck (Pekin) 50g i.p. 2.83
AFM1 Duck (Pekin) 40-50g p.o. Similar to AFB1
AFM2 Duck (Pekin) 40-50g p.o. >4x of AFB1
a p.o. per oral, bi.p intraperitoneal.
Data obtained from (Busby, 1984; IARC, 1993; Cullen and Newberne, 1994; Roebuck and
Maxuitenko, 1994).
Effect of aflatoxicosis on farm animals have been thoroughly studied and reviewed
(Robens and Richard, 1992). They report that swine and cattle fed high doses of aflatoxins
show liver changes such as centrilobular congestion and hemorrhage or increased
prothrombin time, although cattle seem to be less susceptible than swine. Lower aflatoxin
doses may lead to milder hepatic injuries and reduced growth rate, especially in young
animals (Pier, 1992). Cattle and poultry show economically significant effects like reduced
reproductivity and feed efficiency, immunomodulation or reduced milk and egg
production, and poultry is reported to be susceptible to aflatoxicosis (Robens and Richard,
1992).
Aflatoxin B1 requires microsomal oxidation to the reactive AFB1-8,9-epoxide to exert
its carcinogenic effects. This intermediate reacts with DNA, forming persistent adducts,
which induce mutations in somatic cells (Fink-Gremmels, 1999). As for the mechanism of
AFB1 induced mutagenicity and carcinogenicity, AFB1-epoxide adducts to DNA,
preferably guanine nucleotides, causing point mutations mainly G-C to T-A (94%)  or A-T
(6%) (Bailey et al., 1996). Depending on the location this mutation occurs, activation of
proto-oncogenes or silencing of suppressor genes will cause initiation of the cancer
process. Mutations in the p53 tumor suppressor gene at the hot spot of codon 249, are
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discussed in the context of AFB1, but relations between this mutation, AFB1 and hepatitis
B virus infection are not entirely clear (Smela et al., 2001). Following this initial mutation,
cytotoxic effects of AFB1 will further promote cancer development, which leads to the
definition of AFB1 as a “complete carcinogen” (Massey et al., 1995).
Aflatoxin B1 has been demonstrated to be the most potent liver carcinogen known in
different animal species (Pitt, 2000). Several animal studies report the carcinogenicity of
aflatoxins in various species. Trout and rat are the most susceptible species, whereas mice
seem to be relatively resistant to aflatoxin induced carcinogenicity due to effective
glutathione conjugation capability (Dragan and Pitiot, 1994). Busby and Wogan (Busby,
1984) summarized that primary liver tumors induced by oral aflatoxin B1 have been found
in fish (trout, salmon), birds (duck), rodents (rat, mouse, hamster), ferrets and monkeys
(Rhesus monkey, African green monkey). Some animal studies show tumors in several
other organs like colon, glandular stomach and kidneys (Busby, 1984; Dragan and Pitiot,
1994).
2.2.3 Methods to control the aflatoxin problem
A recent outbreak of aflatoxicosis in May 2004 in Kenya (CDC, 2004) has reminded
us that the aflatoxin problem, although being known for decades, has not been solved. Due
to the increasing number of reports on the toxic nature of aflatoxins, there is a need to
control the aflatoxin levels in food and feed. Methods of control can be classified in two
categories: (1) prevention of mold contamination and growth and (2) detoxification of
contaminated products (Riley and Norred, 1999; Mishra and Das, 2003).
The prevention of mold growth can be achieved by pre- or post-harvest strategies.
Potential pre-harvest approaches include measures to reduce crop stress and associated
fungal colonization, the use of non-aflatoxigenic strains of Aspergillus flavus to out-
compete the toxigenic strains, and genetic engineering to produce more resistant crops
(Williams et al., 2004). However, these methods are mainly available for farmers in
developed countries, leaving developing countries without solutions. Post-harvest methods
aim at dry and mold free crops via removing damaged or infected products or using
antifungal agents (Riley and Norred, 1999). A recent post-harvest intervention,
incorporating a package of activities focused on improved crop drying and storage
techniques, successfully demonstrated a greater than 50% reduction in aflatoxin-albumin
adducts in a rural population in West Africa, naturally exposed to AFB1 through diet
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(Turner et al., 2005). In the outbreak of aflatoxicosis in Kenya, improper home storage of
maize was identified as a risk factor for jaundice (CDC, 2004). Detoxification refers only
to post-harvest treatments designed to remove or destroy (decontaminate) the toxin and
therefore reduce the toxic effects (detoxify) of the contaminated product. It can include
physical, chemical or biological methods (Scott, 1998).
Among physical treatments, cleaning and sorting of grain or peanuts as well as
segregation are promising but incomplete methods (Riley and Norred, 1999). The use of
adsorbents added to animal feed is one approach, using hydrated sodium calcium
aluminosilicate (HSCAS) to reduce the bioavailability of aflatoxins (Phillips et al., 2002;
CAST, 2003). Recently, HSCAS have also been demonstrated to be safe for humans
(Wang et al., 2005), which would allow the use of this technique for products intended for
human consumption. Within all chemical treatments, only ammoniation is in extensive
commercial use for cottonseed meal, peanut meal or sunflower meal. Ammonium
degrades aflatoxins to nontoxic metabolites, but it can cause slight changes in the
nutritional quality of feed (Phillips, 1994). Sodium bisulfite, a common food additive, is a
promising detoxification treatment and also ozonization has been found to degrade
aflatoxin in corn at minimal cost and minimal nutrient destruction (CAST, 2003).
Microorganisms like yeasts, molds and bacteria have been tested on their ability to
modify or inactivate aflatoxins. Flavobacterium aurantiacum has been shown to remove
aflatoxin B1 from liquid media (Phillips, 1994) and is used in peanut processing as
biodegrader (Diarra et al., 2005).
However, each of these approaches is limited in applicability to certain products and
complete elimination of contamination is not achieved. Therefore, additional interventions
at the individual level are being sought. The proof of principle in chemoprevention (the
use of chemicals to try to reduce the risk of, or delay the development or recurrence of,
cancer) of aflatoxin toxicity has been demonstrated with oltipraz and chlorophyllin. These
compounds modify aflatoxin metabolism and reduce the biologically effective dose
(Kensler et al., 2004), but this approach is unlikely to be used in practice as drug therapy is
expensive (Williams et al., 2004). More recently the search for chemopreventive agents
has focused on natural products, available and inexpensive, that would modulate aflatoxin
metabolism (activation and detoxification). Numerous phytochemicals including
isothiocyanates and indole-3-carbinol from Brassica species (Kensler et al., 2005);
(Manson et al., 1998), flavonoids  from green tea (Luo et al., 2006) or allicin from garlic
(Berges et al., 2004) are being investigated for their potential to inactivate phase I
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activation and/or induce phase II detoxification. This might, in the future, lead to the
definition of an “anticancerous diet”. Furthermore, probiotic bacteria may also have a
protective effect against AFB1 toxicity, and the following section will describe this
approach in detail.
2.3 Probiotic bacteria
Probiotics are defined by Fuller (Fuller, 1991) as “live microbial food supplements
which beneficially affect the host either directly or indirectly by improving its intestinal
microbial balance”. A probiotic should meet several criteria: a) being able to exert proven
beneficial effects on the host; b) being non-pathogenic and non-toxic; c) being present as
living cells; d) being able to survive the passage through the gut and resistant against
metabolic enzymes; e) being stable and remain viable through storage (Pathmakanthan et
al., 2000). Many probiotic organisms have their origins in fermented foods, and their
“History of safe use” in human consumption allows the status of generally recognized as
safe (GRAS) (Donohue, 2004).
When discussing probiotic bacteria, the term Lactic acid bacteria will often be used.
Lactic acid bacteria (LAB) are a heterogeneous group of Gram-positive, non-sporing, non-
respiring cocci or rods, producing lactic acid as the major end-product of carbohydrate
fermentation and comprise strains from the genera Aerococcus, Alliococcus,
Carnobacterium, Enterococcus, Lactobacillus, Lactococcus, Lactoshaera, Leuconostoc,
Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella
(Axelsson, 2004) . As probiotics, only strains from the genus Lactobacillus (e.g.
L. acidophilus, L. casei, L. bulgaricus, L. reuteri, L. plantarum, L. rhamnosus) are used.
Furthermore, the genus Bifidobacterium, often considered in the same context as
LAB, is phyllogenetically unrelated and has a unique mode of sugar fermentation. Among
them, strains like B. bifidum, B. longum, B. breve, B.  infantis and B.  animalis are
important probiotics (Goldin, 1998; Salminen et al., 2004).
The genus Propionibacterium is of special interest in food production with several
strains being used as dairy starters to produce flavor compounds, carbon dioxide and
propionic acid, a preserving agent (Ouwehand, 2004). In recent studies Propionibacterium
freudenreichii has also been shown to have probiotic properties (Ouwehand, 2004).
Furthermore, some other bacteria, yeast and molds are described as probiotics (Goldin,
1998).
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2.3.1 Beneficial health effects of probiotic bacteria
In recent years many studies aimed at explaining the mechanisms through which
probiotics beneficially affect human health. Salminen and coworkers (Salminen et al.,
1996) report that strengthening of the gut mucosal barrier in healthy subjects could be such
a mechanism and interaction between probiotics and epithelial cells is needed. In order to
increase the time of this interaction, probiotics must adhere to the intestinal surface, as a
first step to its colonization. Adhesion abilities of beneficial bacteria have been widely
studied, using different intestinal substrates such as intestinal mucus of various sources,
intestinal epithelial cells of animal or human origin and from immortalized cell lines
(Tuomola, 1999). Even among different Lactobacilli, adhesion properties vary, and
different possible binding sites including proteins, carbohydrates, or a combination of both
are suggested in the literature (Rojas and Conway, 1996; Tuomola et al., 2000; Rojas et
al., 2002). It is not yet clear, whether different sites are used for adhesion to different
substrates (mucus or intestinal cell), or by different strains of bacteria, or whether all
binding sites are involved simultaneously (Rojas and Conway, 1996; Tuomola et al.,
2000).
One basic mechanism of probiotic action is to modify the normal gut microflora.  The
normal human microbiota is a complex ecosystem, with over 500 different  bacterial
species present in our large intestine and increasing in number from proximal to distal
parts of the intestinal tract (103 CFU/g stomach content to  1012 CFU/g colon content) with
the predominant genera changing from Gram-positive aerobes to Gram-negative anaerobes
(Salminen et al., 1995; Casas and Dobrogosz, 2000). Although different strains of the
genus Lactobacillus (L. acidophilus, L. fermentum, L. plantarum) can be isolated from
feces of 78% of subjects (Conway, 1995), their numbers are generally low and their
importance for a normal function of the gastrointestinal tract is not clearly known.
Bifidobacteria are literally absent in the human adult microflora, even though they form
the predominant genus of the neonate flora (Conway, 1995). It is therefore believed that by
adding these bacteria as probiotics to the diet, the normal flora can be altered. This
alteration might then prevent the adhesion of pathogenic organisms, modulate bacterial
enzyme activity and influence the gut mucosal permeability (Salminen et al., 1996). The
literature available on the potential and proven health effects of probiotics is vast, and only
a brief summary will be presented here.
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Generally, health benefits of probiotics are studied by using single bacterial strains,
and therefore the proven effects can only be defined for one specific strain (Salminen et
al., 2004). To date, the strongest scientifically established evidence for beneficial effect
and clinical use of probiotics in humans is in the management of diarrheal diseases
(Salminen et al., 2004), including antibiotic-associated diarrhea and infective diarrhea
such as Rotavirus diarrhea (Casas and Dobrogosz, 2000) or Traveler’s diarrhea in both
adults and children (Pathmakanthan et al., 2000; Boyle et al., 2006).
Furthermore, the effect of LAB to alleviate symptoms of lactose intolerance and of
food allergies in infants (Salminen et al., 1996; Goldin, 1998; Salminen et al., 2004) is
well established. Numerous studies have focused on immunomodulation by probiotic
treatment, and many potential benefits are discussed [increased serum IgA by viable
Lactobacillus rhamnosus GG (Salminen et al., 1996), stimulated non-specific intestinal
immune reactions with Bifidobacteria (Casas and Dobrogosz, 2000),  prevention of the
development of atopic disease (Kalliomäki et al., 2001)]. These findings are promising for
the future since the incidence of allergies and atopic reactions is increasing.
The potential of probiotics to decrease serum cholesterol has been investigated and
Pathmakanthan et al. (Casas and Dobrogosz, 2000) conclude that strong evidence of
hypocholesterolaemic effects is available in vitro and in vivo in animals, possibly via
deconjugating bile and increasing fecal excretion of bile acids (Lichtenstein and Goldin,
2004).
Antimutagenic and anticarcinogenic effects of probiotics and LAB
Colon cancer is a common health problem in the Western world and its occurrence is
closely related to the diet. A high intake of fruits and vegetables as well as fermented dairy
products may reduce the risk of cancer (Cummings, 1997). The low incidence of colon
cancer in Northern Europe may be linked to a significantly higher intake of dairy products
and cereals in the normal diet (Rafter, 1995).
Many different ways of action are proposed for LAB to reduce the risk of intestinal
cancer They include influencing the mutagenicity of the intestinal content on one hand or
altering the composition and metabolic activity of the intestinal microbiota and therefore
reducing bacterial ?-glucuronidase, ?-glucosidase, nitroreductase and urease on the other
hand (McBain and Macfarlane, 1998; Rowland and Gangolli, 1999; Hirayama and Rafter,
2000). Salminen and coworkers (Salminen et al., 1996) summarize several studies
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investigating antimutagenic and anticarcinogenic effects of probiotics and report that
L. acidophilus significantly reduces the mutagenicity of feces and urine of healthy
subjects. This was confirmed by Hosoda and coworkers (Hosoda et al., 1996) who found
that L. acidophilus LA-2 administered in fermented milk reduced fecal mutagenicity in
male volunteers and that the excretion of Lactobacilli and Bifidobacteria in the feces was
increased in most of the subjects during the intake of LA-2 fermented milk. More
specifically, a reduction in fecal levels of ?-glucuronidase were detected after probiotic
administration (L. acidophilus, L. rhamnosus GG and  L. casei Shirota, several strains of
Bifidobacterium) in colon cancer patients (Salminen et al., 1996) and in healthy subjects
(Casas and Dobrogosz, 2000).
Carcinogen binding has been postulated as a possible mechanism of
anticarcinogenicity of probiotics, and is widely studied in vitro and in vivo. Most
commonly studied are the carcinogenic heterocyclic amines (HCA) [including 2-amino3-
methyl-3H-imidazol(4,5-f)quinoline (IQ), 2-amino3,4-dimethylimidazol(4,5-f)quinoline
(MeIQ), 2-amino-3,8-dimethylimidazol(4,5-f)quinoxaline (MeIQx) and 5-phenyl-2-
amino-1-methylimidazo(4,5-f)pyridine], tryptophane derivatives [including 3-amino-1,4-
dimethyl-5-H-pyrido(4,3-b)indole (Trp-P-1) and 3-amino-1-Methyl-5-H-pyrido(4,3-
b)indole (Trp-P-2) ],  and benzo(a)pyrene (B(a)P).
 Rowland and Gangolli (Rowland and Gangolli, 1999) review several studies about
LAB and their ability to bind food carcinogens and conclude that there is some
experimental evidence in rats that administered LAB decrease the amount of administered
carcinogens reaching the blood.
In vitro evidence shows good binding ability of various probiotic bacteria strains
(B. longum, L. acidophilus, L. delbrueckii ssp. bulgaricus 2038 and Streptococcus
thermophilus 1131) for a range of food carcinogens (PhIP, MeIQ, MeIQx, Trp-P-2,
Trp-P-1 and B(a)P) (Bolognani et al., 1997; Terahara et al., 1998). From in vitro results, it
is also evident that pH dependent differences occur in the carcinogen binding ability of
each strain (Bolognani et al., 1997; Terahara et al., 1998).
In vivo evidence however, is limited to a much smaller range of bacterial strains and
chemicals. B. longum and L. acidophilus did not reduce mutagenicity of heterocyclic
amines in vivo in a host-mediated assay or reduced carcinogen absorption into tissues
when administered to mice (Bolognani et al., 1997). Accordingly, only Streptococcus
thermophilus 1131 inhibited the absorption of Trp-P-1, but not of MeIQx and
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L. delbrueckii ssp. bulgaricus 2038 did not inhibit the absorption of either carcinogen in
vivo in rats (Terahara et al., 1998)
In a more recent study, Zsivkovits and colleagues (Zsivkovits et al., 2003) tested the
DNA protective effect of LAB against heterocyclic amines in vivo in rats. They
administered L. bulgaricus 291, S. thermophilus F4 or V3 and B. longum BB536 to rats
before or at the same time as chicken or beef mix, prepared from fried meats, and found
substantial protection against DNA damage in colonic and hepatic tissues caused by beef
mix with all probiotics used. They concluded that this strong reduction can be partly
explained by bacterial carcinogen binding, and suggest also indirect protective effects. The
same research group published a review, stressing the importance of carcinogen binding
by LAB (Knasmüller et al., 2001). On the other hand, a recent review discussing possible
anticarcinogenic effects of probiotics suggested that carcinogen binding might only play a
minor role (Commane et al., 2005).
2.3.2 Aflatoxin binding by probiotics and LAB
Fermentation of food has been used as a method of preservation for centuries, and
LAB are reported to reduce mold growth and aflatoxin production (Mokoena et al., 2006).
It has been considered that the inhibition of aflatoxin biosynthesis is due to lactic acid or
lactic acid metabolites, which are heat-stable and low-molecular weight compounds
(Gourama and Bullerman, 1995). Furthermore, systemic beneficial effects of probiotics, as
discussed in the previous section, will also play a role in reducing the adverse effect of
aflatoxins in animals and humans. However, this section will focus more on the direct
interaction between the bacterium and the aflatoxin molecule.
Several bacterial strains, of food or human origin, have been tested for their ability to
bind aflatoxins and other mycotoxins to their surface (El-Nezami et al., 2002a; El-Nezami
et al., 2002b; Styriak and Conkova, 2002). El-Nezami and colleagues (El-Nezami et al.,
1998a) found that gram-positive bacteria (five strains of Lactobacillus and one
Propionibacterium) were more efficient in removing aflatoxin from liquid medium than
gram-negative E. coli. Among the five strains of Lactobacillus, L. rhamnosus strain GG
(GG) and strain LC-705 (LC-705), appeared to be most efficient binders for aflatoxin B1,
removing approximately 80% of AFB1 from liquid media within 0 hours of incubation,
which implies that the binding is a very rapid process. These two strains were later
confirmed as most efficient AFB1 binders  among nine stains of Lactobacillus (Haskard et
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al., 2001). Peltonen and coworkers (Peltonen et al., 2001) also studied a range of
Lactobacilli and Bifidobacteria and found remarkable differences in AFB1 binding
abilities, even in strains very closely related. This strain specific AFB1 binding ability of
certain probiotic bacteria strains correlates well with their potential to reduce AFB1
mutagenicity in the Ames assay for Lactobacilli and Bifidobacteria cultured in MRS broth
(Lankaputhra and Shah, 1998) or Lactobacilli cultured in milk (Hosoda et al., 1997).
Besides the specificity of the bacterial strain, also the bacterial concentration
influences the AFB1 removal. Different minimum concentrations have been reported such
as 5 x 109 CFU/ml of either L. acidophilus or B. longum to remove only 13% of the AFB1
within one hour (Bolognani et al., 1997) or 2 x 109 CFU/ml of Lactobacilli and
Propionibacterium to remove 50% of free AFB1 but higher binding occurred at 1010
CFU/ml (El-Nezami et al., 1998a).
When the bacteria are subjected to various chemical and physical treatments, their
ability to remove AFB1 can be increased significantly. Autoclaved cells of L. casei remove
significantly more AFB1 from phosphate buffered saline (PBS) compared to viable
bacteria (Thyagaraja and Hosono, 1994). Heat treatment (boiling for 1 hour) and acid
treatment also significantly enhanced AFB1 binding by GG and LC-705 (El-Nezami et al.,
1998a, b). Peltonen and colleagues compared the binding ability of various strains of
viable and heat-treated Bifidobacteria and found that the viable bacteria bound 4-56%
while heat-treated bacteria bound 12-82% of the AFB1 (Peltonen et al., 2001). In contrast,
Lankaputra and coworkers found that viable bacteria bound more dietary mutagens
(including AFB1) than heat-treated bacteria (Lankaputhra and Shah, 1998).
As heat-treated bacteria are often more efficient to remove AFB1 than viable cells,
metabolic degradation cannot be the mechanism responsible for AFB1 removal. It seems to
be more likely that the toxin is bound to the bacterial surface. The aflatoxin-bacteria-
complex was therefore studied to test the stability of the interaction, and toxin release was
observed after washing the AFB1-bacteria complex with water (Oatley et al., 2000; Lee et
al., 2003). This finding led to the conclusion that the bacteria only reversibly bound AFB1.
However, one study reported that bound AFB1 was only extractable from heat-killed
bacteria, but not from viable ones (Lankaputhra and Shah, 1998).
To elucidate the nature of potential AFB1 binding sites on the surface of Lactobacilli,
bacteria were subjected to various chemical, physical and enzymatic treatments, and cell
wall polysaccharides and peptidoglycanes were found to be responsible for the binding of
AFB1 to the surface of GG and LC-705 (Haskard et al., 2000; Haskard et al., 2001). This
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was further confirmed by Lahtinen and coworkers (Lahtinen et al., 2004) who studied
different cell wall components (exopolysaccharides, cell wall isolates and peptidoglycans)
of GG and concluded that peptidoglycans are the most likely binding sites for AFB1. Heat
treatment may denaturate proteins and lead to the formation of maillard-products while
acid treatment may break glycosidic linkages in polysaccharides and amine linkages in
peptides and proteins and therefore increase the pore size in the peptidoglycane layer of
the bacterial surface (Haskard et al., 2001). This process could allow the binding of AFB1
to the cell wall and would explain the increased binding ability of heat- and acid-killed
bacteria compared to viable bacteria.
Besides these in vitro studies the binding ability of GG, LC-705 and PJS for AFB1
was tested ex vivo in the intestinal lumen of chicks (El-Nezami et al., 2000a). Authors
report that GG removed 54%, LC-705 removed 44% and PJS removed 36% of the AFB1
from the soluble fraction of the luminal fluid within one minute. These results imply that
bacterial AFB1 binding appears under physiological conditions in the animal and that this
could be a way to reduce the bioavailability of aflatoxin in the organism.
In a pilot clinical study the effect of a mixture of LC-705 and PJS on the AFB1 levels
in human feces samples was investigated (El-Nezami et al., 2000b). A significant
reduction in fecal aflatoxin levels was found in subjects after receiving the probiotic
mixture for two weeks compared to subjects receiving a placebo. Authors expected to find
higher levels of AFB1 in the feces of the test group as a result of binding the toxin by the
bacteria and reducing the uptake into the body. They suggest that the time of sampling
(fecal samples were taken one week after commencing the probiotic intervention) may
have allowed the major part of AFB1 in the body to be already excreted in the faeces.
To confirm that the reduction of the AFB1 levels in the feces were not a result of
accumulation of AFB1 inside the intestinal tract, adhesion capability of the AFB1-
probiotic-complex needs to be studied. Kankaanpää and coworkers report that the Caco-2
cell adhesion properties of GG were reduced when the bacteria first bound AFB1 to their
surface (Kankaanpää et al., 2000). Similarly, AFB1 binding by Lactobacillus casei reduced
its subsequent adhesion to HT29 intestinal cells (Hwang et al., 2005). These results are
important, because the adhesion of the probiotic to the epithelium of the intestine is the
first step in its colonization of the gastrointestinal tract. Therefore, the adhesion of the
AFB1-probiotic-complex would increase the time the gastrointestinal tract is exposed to
AFB1.
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This literature review summarized the strong evidence that some specific probiotic
bacteria bind AFB1 in vitro, but only limited information is available on binding under
physiological conditions in the gut in vivo.
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3 Aims
The aims of the work presented in this thesis were to study the binding of aflatoxin B1
by probiotic bacteria under physiological conditions present in the gut and to evaluate
whether this binding would have an impact on the transport and absorption of aflatoxin B1
and its toxic effects. For this purpose, a series of in vitro and ex vivo AFB1 binding studies,
a single dose study in rats in vivo and cell culture experiments were conducted.
Consequently, the specific aims of this work were to:
· Study the ex vivo binding of AFB1 by probiotic bacteria in duodenal loops of
chicks (I), and assess the impact of intestinal mucus on AFB1 binding by probiotics
in vitro (II).
· Assess AFB1 binding by probiotic bacteria and its impact on absorption and
toxicity in vivo in rats (III).
· Investigate the impact of AFB1 binding by probiotic bacteria on the intestinal
AFB1 uptake and toxicity in an intestinal cell culture model (IV).
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4 Experimental
4.1 Bacterial strains
The bacterial strains used were Lactobacillus rhamnosus strain GG (GG, ATCC
53013), Lactobacillus rhamnosus LC-705 (LC-705, DSM 7061), Propionibacterium
freudenreichii ssp. shermanii JS (JS, DSM 7067) and a mixture of the two later (LC-
705+JS). All were obtained from Valio Ltd. (Helsinki, Finland) as a lyophilized powder
and stored at -80°C. Bacterial counts were initially determined by flow cytometry using a
Coulter Electronics EPICS Elite ESP cytometer (Beckman Coulter, Inc. Fullerton, CA,
USA) equipped with an air cooled 488 nm argon-ion laser at 15 mV. Total bacterial counts
were enumerated using the fluorescent emission from SYTO9 (LIVE/DEAD® BacLight™
bacterial viability kit, L-7012, Molecular Probes, OR, USA) at 3.34 mM per 106-107
bacteria. A 525 nm bandpass filter was used to collect the emission for both strains, and
Fluoresbriteä Beads (2.0 mm, Polysciences Inc., PA, USA) were used as an internal
calibration. Later on, bacterial counts were estimated using a spectrophotometer and
adjusting the optical density at 600 nm (A=0.5 corresponds to approximately
1x108 CFU/ml).
 Bacterial suspensions were prepared by weighing lyophilized powder and washing
once with phosphate buffered saline (PBS, pH 7.4), centrifuging (3 000×g for 7 min, 4°C)
and resuspending in PBS (I, II, III), giving final bacterial concentrations of 1-10 x 1010
CFU/0.5 ml. For cell culture experiments, lyophilized bacteria were suspended in PBS,
heat-treated (boiled for 1 hour) and centrifuged (3 000×g for 7 min, 4°C). After washing
once with culture medium (Dulbeco’s Modified Eagle’s Medium, DMEM) containing
antibiotics, they were centrifuged again and then suspended in DMEM containing
antibiotics to have final concentrations of 1-10 x 1010 CFU/0.5 ml.
4.2 Aflatoxin standards and HPLC quantification
Crystalline aflatoxins (aflatoxin B1, M1, G2 and aflatoxicol hereafter abbreviated as
AFB1, AFM1, AFG2 and AFL) were purchased from Sigma Aldrich, St Louis, MO, USA.
Stock solutions were prepared in acetonitrile/benzene (98/2). Methanolic working stocks
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were prepared by evaporating the acetonitrile/benzene mixture and reconstituting in
methanol, AFB1 concentrations were determined spectrophotometrically at 363 nm
??363=21 800 M-1 cm-1) and stocks were stored at -20°C. Aqueous work solutions of
various concentrations were prepared in PBS (I, II), dimethylsulfoxide (DMSO, III) or cell
culture medium (DMEM, IV).
To quantify aflatoxins in various samples reverse-phase HPLC was used (Shimadzu
Model LC-10ADvp solvent delivery system, Shimadzu Model SIL-10Advp auto-injector).
Samples were injected into an ODS Spheri-5 Brownlee column (220 x 4.6 mm, 5 µm;
PerkinElmer Inc., Wellesley, MA, USA) fitted with a C18 guard column (PerkinElmer Inc.,
Wellesley, MA, USA). Two different mobile phases were used for the analysis of either
AFB1 alone or mixtures of AFB1 and its metabolites. For AFB1 analysis (I, II), the mobile
phase was water/acetonitrile/methanol (60/30/10) at a flow rate of 1 ml/min. The retention
time for AFB1 was around 8 min. For analysis of the mixtures of AFs (III, IV) mobile
phase used was ammonium acetate (20 mM, pH 3.9)/methanol/acetonitrile (70/15/15,
v/v/v) at 1.5 ml/min flow rate. The retention times were around 6, 25 and 30 minutes for
AFM1, AFB1 and AFL, respectively. The aflatoxin peaks were detected by fluorescence
detector (RF-10AXL, Shimadzu) at 360 nm (excitation) and 440 nm (emission) and by UV
detector at 360 nm and quantified by a Class VP 5.0 software (Shimadzu Koyoto, Japan).
The assay was carried out at 40°C oven temperature and with an injection volume of 10 µl.
4.3 In vitro AFB1 binding by probiotic bacteria (I, II, IV)
Bacterial suspensions (1-10x1010 CFU/ml either viable or heat-treated) were
centrifuged (3 000×g for 7 min, 4°C) and then suspended in aqueous AFB1 solution (0.1-
64 µM) and incubated at 37°C for 1, 5, 10, 15 or 30 min to allow AFB1 binding. After
incubation for up to 30 min, samples were centrifuged, the amount of free AFB1 in the
supernatant was quantified by HPLC and expressed as percentage of AFB1 added.
Additionally, AFB1 bound to bacterial pellet was extracted twice with 2 ml of chloroform
or methanol. Both extracts were combined, evaporated to dryness under nitrogen stream at
40°C and reconstituted in 0.5 ml methanol for HPLC analysis.
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4.4 Ex vivo binding of AFB1 by probiotic bacteria (I)
For the ex vivo experiment, 80 broiler chicks (age 3 weeks, Vilppulan Hybrid Ltd.,
Vilppula, Finland) were fasted for one day prior to experiments. Animals were
anesthetized with 0.15 ml/100 g body weight of Mebunatâ solution (Orion, Finland) i.p.
containing 60 mg/ml of sodium pentabarbitol. This dose was sufficient to keep the animal
under anesthesia for 60 min. A 2-3 cm cross-sectional cut in the lower abdominal region
was made and a 5-7 cm long segment of the duodenum around the pancreas was separated
by two ligatures. Before tightening the second ligature the test solutions were injected into
the loop. One group (AFB1 group, n=40) received an injection of aflatoxin B1 (8 ?g or 26
nmol/kg body weight in 0.25 ml PBS), and the other group (AFB1 + LC-705+JS, n=40)
received an injection of probiotic mixture LC-705+JS (1011 CFU in 0.25 ml PBS)
immediately followed by an aflatoxin B1 injection (8 ?g or 26 nmol/kg b.w. in 0.25 ml
PBS). Eight chicks from both groups were euthanized at 1, 5, 10, 15 or 30 min after the
injection and the duodenal loops were removed from the carcass. Two animals, not
receiving any injection, were included as untreated controls. Animal studies were carried
out in the animal facilities within the University of Kuopio and were approved by the
Animal Ethics Committee of the University of Kuopio.
Analysis of AFB1 from intestinal content
In order to remove all intestinal content, the duodenal loops were rinsed with 25 ml of
PBS. Content was centrifuged and supernatant and pellet were extracted and treated as
described for in vitro experiments. Bacterial AFB1 binding was calculated by subtracting
the amount of AFB1 in duodenal content of control chicks (no LC-705+JS administered)
from amount of AFB1 in LC-705+JS dosed chicks, and expressed as percentage of the
AFB1 dose.
Analysis of AFB1 from duodenal tissue
The uptake of AFB1 by the intestinal tissue was also investigated. The duodenal loop
was cut into small pieces and homogenized with 10 ml chloroform. The homogenate was
filtered, evaporated to dryness and reconstituted in 0.5 ml of methanol for HPLC analysis.
Recovery of AFB1 from biological fluid and tissue was examined by spiking 1.5 µg of
AFB1 into lumen content and duodenal tissue samples and extracting as mentioned above.
Values were not corrected for recovery.
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4.5 Impact of intestinal mucus on in vitro AFB1 binding by probiotic
 bacteria (II)
The effect of intestinal mucus, present under physiological conditions in the gut, on
aflatoxin binding by probiotic bacteria was tested in the in vitro binding assay. Intestinal
mucus was collected from three porcine colon samples kindly provided by the Animal
Centre of the University of Kuopio. After removing the intestinal content, the tissue was
carefully rinsed with PBS and the mucus layer was gently scraped from the mucosa with a
rubber spatula. After collection, mucus from three animals was pooled and centrifuged (10
min, 13 000×g, 4°C) to remove cellular debris and bacteria. Prior to use, the protein
content of the mucus suspension was determined by a protein assay using a bovine serum
albumin standard (Biorad, Espoo, Finland).
For AFB1 binding experiments, bacteria (GG or LC-705+JS), intestinal mucus and
AFB1 (0.32 - 64.1 µM in 0.5 ml PBS) were mixed either subsequently (forming a bacteria-
mucus complex first, II) or simultaneously (I) and incubated for 1 - 30 min and the AFB1
binding assay was performed as described in section 4.3.
4.6 Impact of probiotic AFB1 binding on absorption and toxicity of
 AFB1 in rats in vivo (III)
To assess whether the binding of AFB1 by probiotics, as observed under in vitro
conditions, will have an impact on the absorption of AFB1 from the gastrointestinal tract
and on its toxic effects, a single AFB1 dose was administered to rats pre-dosed with
probiotics. Animal experiments were carried out in the animal facilities within the
National Public Health Institute (KTL) in Kuopio and were approved by the Animal Ethics
Committee of the University of Kuopio.
28 male Han-Wistar rats (age 5 weeks) were provided from the breeding facilities of
the University of Kuopio. Rats were kept individually in metabolic cages and maintained
on standard powdered feed (R36, Lactamin, Stockholm, Sweden) and water ad libitum.
They were under a photoperiodic cycle of 12 h light/12 h dark in an air-conditioned room
with the mean temperature of 21.0±0.2°C and the relative humidity 50±3%. After an
acclimatization period of 3 days, 24 animals were divided into two groups (n=12
rats/group). Group one received the vehicle (PBS) and group two the probiotic strain GG
(5x1010 CFU/0.5 ml PBS) by oral gavage daily for 6 successive days. Immediately after
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the fourth GG dose, animals of both groups received a single oral dose of AFB1 (1.5 mg or
4.8 ?moles/kg b.w. in 0.5 ml DMSO). Four additional rats served as untreated controls.
Body weight was recorded at the beginning of the study (prior to GG treatment), on the
day of AFB1 dosing, and at the end of the study. Urine and feces were collected daily,
weighed and stored in -20°C until analysis. At the end of the study rats were anesthetized
by CO2 inhalation and blood samples were taken by cardiac puncture into heparinized
Venoject 5 ml blood collection tubes (Terumo Europe N.V., Leuven, Belgium). After
centrifugation the plasma samples were stored at -20°C. Alanine transaminase (ALT)
activity, a marker for liver injury of AFB1, was measured in rat plasma using a commercial
kit (Konelab, Thermo Electron Corp., Waltham, MA, USA).
4.7 Analysis of biological samples for AFB1 and its metabolites
Analysis of AFB1-albumin adducts from rat plasma
The levels of AFB1-albumin adduct were determined by albumin extraction, digestion
and ELISA as previously described (Chapot and Wild, 1991). The detection limit was 5 pg
AFB1-lysine equivalents per mg of albumin (pg/mg). Three positive and one negative
control samples were analyzed with each batch of samples. Samples were measured in
quadruplicates on two separate days with CVs below 25%.
Analysis of AFB1 and AFM1 from fecal samples
Extraction of fecal samples was modified from a method developed in our laboratory
(Mykkänen et al., 2005). After collection, fecal samples were weighed and stored in
plastic bags at -20ºC until analysis. Samples were mixed for 180 seconds (Stomacher 400
Laboratory Blender, GW Berg & Co, Vantaa, Finland) with 2.5 x volume of 0.2 M sodium
acetate in 10% NaCl. Aliquots (2 ml) of the mixture were spiked with AFG2 (18.6
pmol/sample) as internal standard and centrifuged (3000×g, 15 min, 4ºC). Pellets were
suspended in 4 ml 80% methanol (in 10% NaCl, v/v), vortexed and homogenized
thoroughly (MICCRA D-8, ART Labortechnik, Mühlheim, Germany). Following a second
centrifugation, the supernatant was reduced to a volume of 1 ml (under N2-stream, 50°C),
diluted with 9 ml of Milli-Q water and aflatoxin residues were isolated using solid phase
extraction columns (Strata C18-E 55um, 70A, Phenomenex, Fenno Medical, Vantaa,
Finland). Columns were pre-activated with 10 ml methanol followed by 10 ml Milli-Q
water. Samples were loaded at a flow rate of 1 ml/min and columns were washed with
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5 ml of 5% methanol. Aflatoxin residues were eluted from the columns with 3 ml of
acidified methanol (0.5% acetic acid in 50/50 methanol/water) followed by 5 ml of
methanol, evaporated to approximately 100 µl volume and diluted with 2 ml of Mili-Q
water for Immuno affinity column (IAC) cleanup. IACs (AflaTest, Vicam, Fleurs,
Belgium) were washed with 10 ml PBS and 10 ml MQ-water. Samples were loaded,
washed with 5 ml PBS and 10 ml MQ-water and eluted with 4 ml of 95% methanol.
Cleaned samples were evaporated to dryness under vacuum (SPD1010 SpeedVac®
System, Thermo Savant, Waltham, MA, USA), reconstituted in 500 µl methanol and
stored at -20°C prior to HPLC analysis.
Analysis of AFM1 from urine samples
After collection, urine samples were weighed, acidified with 0.1 N HCl to pH 5, and
centrifuged (3 000×g, 15 min, 4ºC). Supernatants were stored at -20°C until analysis.
Urine (0.5 ml) was spiked with AFG2 as internal standard (9.3 pmol/sample) and aflatoxin
residues were isolated with solid phase extraction columns and cleaned with IAC as
described above for fecal samples. Cleaned samples were evaporated to dryness,
reconstituted in 500 µl methanol and stored at -20°C as described above.
4.8 Quantification of fecal and urinary AF levels
All fecal and urine samples were spiked with AFG2 (18.6 and 9.3 pmol per sample,
respectively) as an internal standard prior to extraction and analysis. Peak areas of analytes
in the fecal and urine samples after HPLC analysis were corrected for day to day variation
to a mean AFG2 peak area, as determined from spiking of negative control fecal and urine
samples with AFG2 and consequent extraction and analysis (spiking of 6 samples per
matrix, extraction on two different days, with AFG2 levels applied in the 'real' urine and
fecal samples). Quantification of AFB1 and AFM1 levels in feces and urine was done by
calculation of analyte concentration from AFB1 and AFM1 standard curves created in feces
and urine. The negative control samples for feces and urine were spiked with AFB1 (all
spikings were done in triplicates; for feces: 5 points with concentrations from 0.32-
4.8 µM; for urine: 6 points from 0.16-3.2 µM) and with AFM1 (feces: 5 points from 0.03-
0.46 µM; urine: 6 points from 0.03-0.61 µM), and standard curves were drawn. From the
corrected analyte peak areas (correction for AFG2 internal standard as described above),
the concentrations for AFM1 and AFB1 in the samples were calculated from the standard
47
curve equations. Daily and total excretion in feces and urine were calculated based on total
volumes of urine and feces. AFM1, AFB1 and AFG2 peak identities in the urine and fecal
samples were confirmed via spiking experiments with the respective toxin standards and
reanalysis with HPLC.
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Figure 5: Representative HPLC chromatograms of samples before (black trace) and after
(grey trace) spiking experiments. Panel A shows a rat fecal sample spiked with AFM1,
AFG2 and AFB1 standards and Panel B shows a rat urine samples spiked with AFM1 and
AFG2.
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4.9 Impact of probiotic binding on AFB1 uptake and toxicity in Caco-2
 cells (IV)
These experiments were carried out to assess transport and toxic effects of AFB1 in a
cell culture model in the absence and presence of probiotics. Additionally, these
experiments aimed at evaluating the feasibility of the Caco-2 cell culture model for
studying probiotic AFB1 binding and its impact on its intestinal absorption and toxicity.
4.9.1 Cell line and culture conditions
The human colon cancer cell line Caco-2 (ATCC, HTB-37) was cultivated according
to standard procedures in Dulbeco’s Modified Eagle’s Medium (DMEM, Cambrex Bio
Science, Verviers, Belgium) with 20% fetal bovine serum  (FBS, Invitrogen, Paisley, UK)
and 0.2 % antibiotic/antimycotic (20 IU/ml penicillin, 20 ?g/ml streptomycin, 0.05 mg/l
amphotericin B, Invitrogen, Paisley, UK) and cultures were kept at 37°C with 5% CO2.
Monolayers were passaged at ~80% confluency with 0.05% trypsin-0.02% EDTA
(Invitrogen, Paisley, UK). For experiments, cells were seeded in 12-well plates (9x104
cells/ml) and grown for 21 days until cells differentiated into small intestinal cells
containing microvilli.
4.9.2 Induction with 1?,25-dihydroxyvitamin D3
The cell line has low expression of a key enzyme, CYP 3A4 that generates the
aflatoxin epoxide. This enzyme was induced by pre-incubation with 1?,25-
dihydroxyvitamin D3 (1,25(OH)2D3) (Schmiedlin-Ren et al., 1997). DMEM containing
0.25 µM 1,25(OH)2D3 was added onto the cell monolayer on day 21 and left for 2 or 5
days.
The extent of CYP 3A4 induction was assessed by testing AFB1 bioactivation in
microsomes extracted from Caco-2 cells. Cells (105cells/ml) were seeded for microsomal
protein extraction in 75 cm2 flasks (Nunc, SLS, Nottingham, UK) in a volume of 25 ml
cell culture medium. Undifferentiated cells were grown for 3 days, whilst differentiated
cells were grown for 21 days, prior to treatment. Flasks were treated with 0 or 250 nM
1,25(OH)2D3 in 0.05% ethanol for 48 hours. Caco-2 microsomes were isolated by cell
lysis, repeated centrifugation and protein quantitation (Biorad, Espoo, Finland).
Microsomal protein samples were incubated with aflatoxin, essentially as described earlier
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(Kirkby et al., 1993). Pooled rat liver microsomes (Invitrogen, Paisley, UK) were used as a
positive control for aflatoxin metabolism. 100 ml incubation buffer [80 mM phosphate
buffer (pH 7.4), 75 mM tris-HCl (pH 7.4), 5 mM MgCl2, 0.39 mM NADP+, 6 mM
glucose-6-phosphate and 0.37 U of glucose-6-phophate dehydrogenase] were mixed with
AFB1 (64 mM) and 1 mg microsomal protein and incubated at 37°C for 15 min. The
reaction was stopped by addition of 500 ml of ice-cold methanol to each sample. Samples
were centrifuged (16 450×g, 15 min, 4°C). The supernatant was retained and the pellet
washed with 500 ml ice-cold methanol and centrifuged as above. The combined
supernatants were evaporated to dryness (SPD1010 SpeedVac® System, Thermo Savant,
Waltham, MA, USA) and the residue reconstituted in 500 ml water/methanol (1/1, v/v)
before centrifugation at 2000×g for 5 min at 4°C. The supernatant was subsequently
analyzed by HPLC.
4.9.3 Transport of AFB1 and formation of free metabolites
For transport experiments, cells were grown on Transwell® filter inserts (12 mm
diameter, 0.4 µm pore size, Corning Inc., Corning, NY, USA), with media volumes of 0.5
ml in the apical and 1.5 ml in the basolateral chamber. Media was changed three times per
week and cells were differentiated for 21 days. Following induction with 1,25(OH)2D3, the
transport of AFB1 from the apical to the basolateral side was investigated as described
previously (Mata et al., 2004) with modifications. GG suspension (1 or 5x1010 CFU/ml)
and AFB1 solution in DMEM (150µM) were added to the apical chamber of filters and
plates were placed on a plate shaker (300 rpm/min) to prevent the bacteria settling on the
monolayer. Aliquots (15 µl) of culture medium were taken from both chambers at 0.5, 1,
24, 48 and 72 hours after AFB1 addition. Aliquots were centrifuged to remove free cells
and bacteria, diluted with Milli-Q water when necessary and injected into HPLC for
analysis of AFB1, AFM1 and AFL. Furthermore, AFB1 bound by GG was removed from
the bacterial pellet after centrifugation by extracting twice with 0.5 ml methanol, and
injected into HPLC. For the transport of AFB1 through the monolayer, permeability
coefficients (Pe) were calculated as Pe = Vd/Ax?%/?t where Vd is the volume of the
donor compartment, A is the surface area of the monolayer, and ?%/?t is the percentage
mass transported per second (Mata et al., 2004). The identities of metabolites (AFM1 and
AFL) were confirmed via spiking samples of cell culture medium with respective aflatoxin
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standards and reanalyzing by HPLC. Amounts of metabolites were calculated by
comparing peak areas of samples with peak areas of standards.
4.9.4 Assessment of AFB1 induced membrane damage (TER)
Transepithelial resistance (TER) is a measure of membrane integrity, using two
electrodes to measure the electrical potential difference (expressed as ?/cm2) between the
apical and basolateral chamber of the two compartment model. Differentiation and AFB1
induced membrane damage were monitored by changes of transepithelial resistance
(EVOM TER-meter, World Precision Instruments, Sarasota, FL, USA). Experiments were
carried out as mentioned above, and TER readings were recorded from filters during
differentiation, after 1,25(OH)2D3 induction and after addition of GG (1 or 5x1010
CFU/ml) and AFB1 (150 ?M). Measurements were always carried out following the
addition of fresh culture medium. Following the final measurement, cells were trypsinized
and cell viability was assessed using trypan blue exclusion assay. Cell viability was always
high (>90% viability).
4.9.5 Assessment of AFB1 induced DNA damage (Comet assay)
Caco-2 cells were differentiated on 12 well plates for 21 days and induced with
1,25(OH)2D3 for 5 days. Following 24 or 72 hours of incubation with GG (1 or 5x1010
CFU/ml) and AFB1 (100 or 200 ?M), the cells were harvested using trypsin-EDTA and
viability was assessed with trypan blue staining. Only cells with viability > 90% were used
for further assays. DNA damage was assessed using single-cell gel electrophoresis (Comet
assay). Single-cell suspensions were prepared in 0.8% low melting point agarose, (in PBS,
pH 7.4), placed on a microscope slide pre-coated with 1% agarose and allowed to solidify.
Slides were then submerged in detergent solution (2.5 M NaCl, 1 mM EDTA, 10 mM Tris,
10% DMSO and 1% Triton-x, pH 10) for 1 hour to disrupt the cell membranes and washed
three times in enzyme buffer (40 mM Hepes, 0.1 M KCl, 0.5 mM EDTA, 0.3 ml 30%
bovine serum albumin/500 ml buffer, pH 8) for 5 min before the addition of 50 µl of Fpg
enzyme (formamidopyrimidine [fapy]-DNA glycosylase, diluted in enzyme buffer) or
enzyme buffer alone to each slide. Slides were covered with coverslips and incubated at
37°C for 30 min. After removing coverslips, slides were placed in an alkaline
electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, pH>13) for 40 min, allowing the DNA
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to unwind. Subsequently slides were transferred to an electrophoresis chamber at 23V
(variable amplitude) for 20 min. After rinsing with neutralizing buffer for 5 min (0.4 M
Tris base, pH 7.5), nuclear DNA was stained with ethidium bromide ? ? (25 mg/ml). Comets
were viewed using fluorescent microscopy and quantified as a percentage of the total
DNA in the comet tail using ‘Komet 4.0’ software (Kinetic Imaging Ltd, Merseyside,
UK).
4.10 Statistics
SPSS® 11.5 for Windows was used for statistical analysis and data were subjected to
either Student’s t-test or Mann-Whitney U-test. Significant differences in the mean values
are reported at p ? 0.05.
52
5 Results
5.1 AFB1 binding characteristics of the probiotics used
In this study two different probiotic preparations were used, Lactobacillus rhamnosus
strain GG (GG) (II, III and IV) and the probiotic mixture of Lactobacillus rhamnosus
strain LC-705 and Propionibacterium freudenreichii ssp. Shermanii JS (LC-705+JS) (I,
II). The abilities of these strains to bind AFB1 in vitro as viable or non-viable preparations
and at different bacterial counts are summarized in Table 1.
Table 2: Percentages of AFB1 (4.8 ?M) bound in vitro by GG and LC-705+JS after 30
min.
% AFB1 bound (±SD)
Probiotic/number GG LC705+JS
Viable Heat-treateda Viable Heat-treated
1x1010 CFU/ml 26.4 (±0.6) 43.3 (±0.8) 21.7 (±1.1) 28.4 (±1.2)
5x1010 CFU/ml 60.2 (±1.1) 69.1 (±1.0) 43.2 (±0.5) 50.6 (±0.7)
10x1010 CFU/ml 76.3 (±0.5) 82.8 (±0.6) 58.3 (±0.9) 77.3 (±0.9)
aBacterial suspensions in PBS were boiled for 1 hour.
In this study, both probiotics bound AFB1 efficiently, although binding percentages
for the mixture LC-705+JS were always below the values obtained for GG. Heat treatment
enhanced AFB1 binding ability of both probiotics. However, to perform other beneficial
probiotic effects, bacteria have to be administered viable, which explains the use of viable
bacteria in most of our studies (I, II, III).
The first part of this thesis work was conducted to assess the binding ability of the
probiotic mixture under physiological conditions at a bacterial count high enough to exert
sufficient AFB1 binding (10x1010 CFU/ml).
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5.2 Probiotic AFB1 binding ex vivo and the impact of intestinal mucus
 on in vitro binding (I, II)
To assess probiotic AFB1 binding and its absorption ex vivo, AFB1 was measured in
the luminal content and duodenal tissue of chicks injected with a single dose of AFB1
alone or AFB1 and probiotic (LC-705+JS). The percentage of AFB1 retained inside the
lumen in the presence of probiotic was significantly (p<0.01) higher at all time points (9 to
39%) compared to the group injected AFB1 alone (4 to 14%, Figure 6). In the negative
controls, no AFB1 was detected in the duodenal content and tissue.
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Figure 6: Percentage AFB1 recovered from duodenal lumen content and duodenal tissue
of chicks injected (instilled into duodenal loop) either AFB1 (4.8 µM) only or AFB1 and
probiotic mixture LC705+JS (1011 CFU/0.5 ml). Values are means of 8 animals ± SD.
Less AFB1 was detected in duodenal tissues of chicks injected with both probiotics
and AFB1 after 1, 5, 10 and 30 mins when compared to chicks injected with AFB1 alone
(Figure 6). This indicates a 40% reduction in the uptake of AFB1 by the duodenal tissue
after 1 minute when the probiotic mixture was present. From results in Figure 6, the % of
AFB1 bound by bacteria can be estimated by substracting amounts of AFB1 present in
duodenal lumen in the absence of probiotic mixture from amounts present in the presence
of probiotics (% AFB1 bound = % AFB1 in content of AFB1 alone group - % AFB1 in
content of AFB1 and LC-705+JS group). This suggests that only 25% of the AFB1 dose
were bound by LC-705+JS (1011 CFU /ml) initially after 1 min, and the fraction of AFB1
bound by the probiotic mixture decreased over time (5% bound after 30 min). In order to
explain this lower AFB1 binding efficiency ex vivo, further experiments were carried out in
vitro, to test the effect of intestinal mucus on the AFB1 binding by probiotics.
54
Impact of bacterial mucus binding on AFB1 binding
The addition of intestinal mucus clearly reduced the binding ability of both probiotics
tested (GG and LC-705+JS). However, the effect of mucus was more pronounced for the
mixture LC-705+JS (13.6±2.1 vs. 5.3±0.6% of AFB1 bound in the absence and presence of
mucus) than for GG (20.9±0.8 vs. 16.0±1.4% of AFB1 bound in the absence and presence
of mucus) (Figure 7), although GG was able to bind more intestinal mucus (40% of the
mucus added) in comparison to LC-705+JS (15%) (II).
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Figure 7: Effect of mucus (10 mg/ml) on AFB1 binding at different AFB1 concentrations
(0.32 - 64.1 µM) by viable Lactobacillus rhamnosus GG (GG) and a mixture of
Lactobacillus rhamnosus LC-705 and Propionibacterium freudenreichii ssp. Shermani JS
(LC-705+JS) at 1x1010 CFU/ml. Values are means of four replicates.
Furthermore, a lower amount of mucus was necessary to significantly reduce AFB1
binding by LC-705+JS compared to GG (II) and mucus decreases AFB1 binding  by
probiotic mixture in a concentration dependent manner (Figure 8). Addition of mucus with
a protein concentration of 3 mg/ml could not decrease AFB1 binding significantly at any
time point, whereas addition of higher concentrated mucus (6 mg protein/ml) reduced
AFB1 binding by bacteria significantly (p<0.05) after 5, 10, 15 and 30 min incubation time
(Figure 8). However, despite the obvious impact of intestinal mucus on AFB1 binding, the
level of binding ex vivo is still lower compared to in vitro results (Figure 8).
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Figure 8. Percentage of AFB1 (10?M) bound by 1011 CFU of LC705+JS calculated (AFB1
added - free AFB1 in supernatant), extracted with 2-fold chloroform extraction, in the
presence of mucus containing 3 or 6 mg/ml protein, and recovered from the lumen content
in the chick. Ex vivo samples were corrected with the values of AFB1 alone to show only
bound AFB1. Values are means of 3 replicates in vitro and 8 animals ex vivo.
5.3 Impact of probiotic AFB1 binding on absorption and toxicity of
 AFB1 in rats in vivo (III)
In order to assess the bacterial AFB1 binding and its effects in vivo, a single oral AFB1
dose was given to rats which were dosed with either probiotic suspension (5x1010 CFU/0.5
ml GG) or vehicle daily for 3 days before and 3 days after AFB1 dosing.
AFB1 binding in vivo
Bacterial AFB1 binding was tested in vivo by measuring AFB1 levels in feces of rats
for 3 days following a single oral AFB1 dose. Fecal AFB1 levels were highly variable
between animals and remained very low in all animals (cumulative fecal excretion over 3
days was 5.3 and 6.8% of the dose for rats in AFB1 only and AFB1+GG group,
respectively, III). Fecal excretion of AFB1 was increased by 2.2 fold within the first day
after the AFB1 dose in the group receiving AFB1 and GG as compared to that receiving
AFB1 alone (35.3±21.3 vs. 15.6±9.8 nmol/24 hour feces, p=0.015), whereas no difference
was observed on days 2 and 3 after AFB1 dosing (Figure 9).
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Figure 9: Effect of Lactobacillus rhamnosus strain GG (GG) on daily fecal AFB1
excretion over three days following a single dose of AFB1 (1.5 mg or 4.8 µmol/kg b.w.).
Values represent means±SD (n=12 rats/group).
The percentage of AFB1 bound by probiotics in feces can be calculated by comparing
AFB1 levels in rats dosed with or without probiotic administration. This shows that
additional 19.7 nmoles AFB1/24 hour feces are excreted in feces due to probiotic binding.
Intestinal metabolism
In vivo metabolism of AFB1 in the intestine was assessed by measuring AFM1 levels
in rat fecal samples. The 3 day cumulative excretion of AFM1 was 5.4% of the dose
(Figure 10).
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Figure 10: Effect of viable Lactobacillus rhamnosus strain GG (GG) on excretion of
AFM1 in feces of rats over three days following a single dose of AFB1 (1.5 mg or 4.8
µmol/kg b.w.). Values represent means±SD (n=12 rats/group).
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The levels of AFM1 detected in feces one day after AFB1 dosing were significantly
higher in the group receiving AFB1 and GG as compared to animals receiving AFB1 only
(68.1±26.1 vs. 27.1±22.5 nmol/24 hour feces, p=0.001). On days 2 and 3 following the
AFB1 dosing no difference between the groups was observed.
AFB1 absorption
AFB1-albumin adducts were detected in the plasma of all rats receiving AFB1, but not
in the plasma of the untreated controls. The mean levels of AFB1-albumin adduct in both
groups were highly variable and tended to be reduced in the group receiving AFB1 plus
GG as compared to that receiving only AFB1 (13.8±4.5 vs. 19.5±10.1 ng/mg albumin,
29% reduction), although this reduction was not statistically significant (p=0.149). No
change in urinary AFM1 levels was observed in rats receiving AFB1+GG when compared
to rats receiving AFB1 alone (Figure 11).
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Figure 11: Effect of Lactobacillus rhamnosus strain GG (GG) on daily urinary AFM1
excretion in rats over three days following a single dose of AFB1 (1.5 mg or 4.8 µmol/kg
b.w.). Values represent means±SD (n=12 rats/ group).
Toxic effects on liver function and body weight
The activity of alanine transaminase (ALT) in plasma, an indictor of liver injury, was
highly variable. ALT activity was similar in the control and AFB1 plus GG groups
(41.6±18.7, n=4 and 56.4±34.2 U/l, n=9, respectively, p=0.317), while a trend towards
increased ALT activity was seen in the group receiving AFB1 alone (103.7±84.9 U/l, n=9,
p=0.053) as compared to controls.
Body weight of animals in the beginning of the study was similar in all groups
(156.0±23.1 for untreated controls, 155.0±8.0 for the group AFB1 only, and 154.8±7.9 for
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the group AFB1+GG). During the duration of the study the untreated control animals
gained 8.2±2.0 g/day. Prior to AFB1 dosage the daily body weight gain of the treatments
groups were similar (7.0±0.9, p=0.211 and 7.2±1.2 g/day, p=0.332 for AFB1 alone and
AFB1+GG, respectively) and not different from the body weight gain in untreated
controls. During three days following AFB1 dosing, the reduction in daily body weight
gain was significantly more pronounced in animals receiving only AFB1 (-3.12±2.94 g
gain/day) whereas those receiving GG maintained their weight (0.04±2.19 g gain/day,
p=0.011, Figure 12).
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Figure 12: Effect of Lactobacillus rhamnosus strain GG (GG) on daily body weight gain
before and after a single dose of AFB1 (1.5 mg or 4.8 µmol/kg b.w.). Values represent
means±SD (n=4 rats/group for untreated controls and n=12 rats/group for rats receiving
AFB1 only or AFB1 and GG).
5.4 Impact of probiotic binding on AFB1 uptake and toxicity in Caco-2
 cells (IV)
In experiments using Caco-2 cells, GG and AFB1 were added to the apical chamber or
a two compartment dish and samples were taken from both apical and basolateral
chambers, to assess the effect of AFB1 binding by GG on AFB1 transport across the
epithelia. From the apical compartment, both free AFB1 in supernatant and AFB1 bound
by GG from the pellet after centrifugation were determined. Bacteria (1 and 5 x 1010
CFU/ml) reduced the amount of free AFB1 in the apical chamber by binding 40.1±5.5 and
61.0±6.0% of AFB1 added after 1 hour and 18.0±2.8 and 40.9±2.5% after 24 hours,
respectively (Figure 13).
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Figure 13: Percentage of AFB1 (150 ?M) recovered free from culture medium (apical and
basolateral) and bound by 0, 1 or 5 x1010CFU/ml GG (apical). Apical and basolateral
culture medium was removed after 1 or 24 hours incubation, centrifuged and supernatant
was injected into HPLC. Bacterial pellet (apical) was extracted with methanol to remove
AFB1 bound by GG. Values are presented as means of 2 replicates and 2 repeated
experiments, error bars refer to standard deviation.
From results of transport experiments, a permeability coefficient can be calculated, to
estimate the transport of aflatoxin through the monolayer (Figure 14).
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Figure 14: Permeability coeffiecients (Pe) for AFB1 transport through the Caco-2
monolayer calculated as Pe = Vd/Ax?%/?t (Vd = volume of the donor compartment, A =
surface area of the monolayer, ?%/?t = percentage mass transported per second (Mata et
al., 2004). Values are presented as means of 2 replicates and 2 repeated experiments, error
bars refer to standard deviation.
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The permeability of AFB1 (24.6±3.3x10-6 cm/sec) was reduced slightly in the
presence of 1x1010 (17.2±6.1x10-6 cm/sec, p=0.06) and significantly with 5x1010 CFU/ml
(7.0±4.8x10-6 cm/sec, p=0.005).
Formation of AFM1 and AFL by Caco-2 cells
In the Caco-2 model, we assessed the formation of free AFM1 and AFL, both
metabolites of AFB1 released into the culture medium of the apical (Figure 15) and
basolateral chamber (data not shown).
Figure 15: Effect of heat-treated Lactobacillus rhamnosus strain GG (GG, 1 and 5x1010
CFU/ml) on the formation of AFL (panel A) and AFM1 (panel B) in differentiated Caco-2
cells measured in culture medium of apical chamber at 3 time points (24, 48 and 72hours)
after AFB1 addition (150?M). Values are presented as means of 2 replicates and
2 repeated experiments, error bars refer to standard deviation.
Without bacteria present, AFL and AFM1 were detectable in the culture medium of
both compartments after 24 hours of incubation of Caco-2 cells with AFB1 and the levels
of both metabolites formed increased further after 48 and 72 hours of incubation
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(Figure 15). In the presence of GG, the formation of AFL was reduced in both chambers
(apical Figure 15, basolateral data not shown), at both bacterial concentrations and all time
points, as could be expected after reduced AFB1 uptake. Surprisingly, AFM1 formation
was increased in the presence of GG rather than decreased, as would be expected after
bacterial binding decreased AFB1 uptake.
Intestinal toxicity
For AFB1 to perform a toxic effect on Caco-2 cells, induction of CYP 3A4 enzymes is
required, for AFB1-epoxide formation to occur. Therefore, Caco-2 cells were pretreated
with 1,25(OH)2D3 prior to toxicity assays. TER readings (Transepithelial resistance, a
measure for intestinal membrane integrity) increased over 3 weeks of differentiation of the
Caco-2 cells, and reached a plateau towards day 21. AFB1 induced decrease in TER
readings was only observed in cells preincubated with 1,25(OH)2D3 (Figure 16).
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Figure 16: Effect of heat-treated Lactobacillus rhamnosus strain GG (GG, 1x1010
CFU/ml) on transepithelial resistance (TER) in differentiated Caco-2 cells (following
induction with 1,25(OH)2D3 for 48 hours) measured in culture medium of apical and
basolateral chamber at 3 time points (0, 24 and 48 hours) after AFB1 addition (150 ?M).
Values are presented as means of 2 replicates and 2 repeated experiments, error bars refer
to standard deviation.
Incubating 1,25(OH)2D3 induced Caco-2 monolayer with 150 ?M of AFB1
significantly decreased the TER ratio (calculated as TER tinc/TER t0) readings after 24
(0.69±0.04) and 48 hours (0.46±0.02) of incubation (Figure 16). In the presence of
probiotic bacteria (1x1010 CFU/ml), this aflatoxin induced decrease in TER reading is
attenuated after 24 hours (0.82±0.02, p=0.002) and 48 hours (0.52±0.01, p=0.04)
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incubation, suggesting that bacteria were able to reduce AFB1 induced toxicity. Higher
bacterial numbers and longer incubation times were not suitable for this assay, since
bacteria started to influence TER readings, independent of the presence of AFB1.
As marker of AFB1 induced DNA damage in the cells, DNA fragmentation was
assessed in Caco-2 cells exposed to AFB1 following induction of CYP 3A4 induction,
using the Comet assay to quantify the extent of DNA damage. No DNA damage was seen
in the comet assay when Caco-2 cells were incubated either GG, 1,25(OH)2D3 or AFB1
alone (Figure 17).
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Figure 17: Effect of heat-treated Lactobacillus rhamnosus strain GG (GG, 1 and 5x1010
CFU/ml) on DNA damage in differentiated Caco-2 cells (following induction with
1,25(OH)2D3 for 5 days) measured with the Comet assay after AFB1 addition (200 µM, for
24 or 72 hours). Values are presented as means of 2 replicate slides (50 cells/slide) and
2 repeated experiments, error bars refer to standard deviation. *indicates significant
difference (p<0.001) compared to cells incubated without GG.
DNA damage occurred after incubating 1,25(OH)2D3 induced Caco-2 with AFB1
(200 ?M, 35.5±11.3 and 63.3±14.0% tail DNA after 24 and 72 hours incubation,
Figure 17). A significant (p<0.001) reduction in DNA damage was observed after 24 hours
only at the higher GG concentration (5x1010 CFU GG/ml) (22.8±10.8% tail DNA) and
after 72 hours at both GG concentrations (48.1±18.3 and 33.7±14.9% tail DNA for 1 and
5x1010 CFU GG/ml, Figure 17). Furthermore, AFB1 at lower concentrations (100 and
150 ?M) also caused DNA damage (40.8±17.8 and 52.7±14.7% tail DNA after 72 hours
incubation), but GG had no effect on these values (data not shown).
*
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*
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6 Discussion
Probiotic bacteria have been studied intensively for their potential to bind food grade
carcinogens, including mycotoxins. A series of studies has identified Lactobacillus
rhamnosus strain GG as a very potent AFB1 binding strain (El-Nezami et al., 1998a, b;
Haskard et al., 2001), and it was used as a benchmark in the studies presented here.
Furthermore, the probiotic mixture of Lactobacillus rhamnosus strain LC-705 and
Propionibacterium freudenreichii ssp. Shermanii JS (LC-705+JS) was used in this study,
since it is used by food and feed industry as antifungal agent (BioprofitTM) and was used in
a pilot clinical trial in Egypt (El-Nezami et al., 2000a) and a intervention trial in China (El-
Nezami et al., 2006), both aimed at reducing naturally occurring AFB1 exposure in human
subjects.
6.1 Probiotic AFB1 binding ex vivo and the impact of intestinal  mucus
on in vitro binding (I, II)
The duodenal loop technique in chicks has proven useful for AFB1 binding and
intestinal uptake studies before (El-Nezami et al., 2000a), combining many advantages of
providing “real life” intestinal conditions and at the same time having easy access to the
intestine to inject test solutions and take samples at various time points.  In this earlier
study (El-Nezami et al., 2000a), GG, LC-705 and JS bound AFB1 very efficiently after 60
mins, and the uptake into the duodenal tissue was prevented. In the present study (I), AFB1
binding probiotic mixture LC-705+JS was between 39% after 1 min and only 4% after 30
mins. Furthermore, AFB1 absorption into duodenal tissue could only be retarded, but not
prevented by probiotic mixture LC-705+JS. These findings led to the question, which
factors inside the intestinal lumen of animals could have interfered with AFB1 binding in
such strain-specific manner, reducing binding capacity of the probiotic mixture, but not
that of the individual probiotic strains studied before. From the literature it was evident
that in vitro assays, e.g. for probiotic adhesion studies, can be modified to include gastric
pH, digestive enzymes or intestinal mucus. Previous AFB1 binding studies clearly showed
that addition of HCl did not reduce but rather enhancd bacterial AFB1 binding by all three
probiotic strains used in the present studies (El-Nezami et al., 1998a, b; Haskard et al.,
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2000), and that digestive enzymes like lipase (Haskard et al., 2000) or proteases such as
pronase E (Haskard et al., 2000), trypsin or ?-chymotrypsin (Lahtinen et al., 2004) had no
effect on AFB1 binding by GG.
From intestinal adhesion studies with probiotics it is evident that bacteria have
receptors on their surface, enabling them to bind to intestinal epithelial cells and intestinal
mucus. Mucin binding proteins have been identified on the surface of probiotic bacteria
(Rojas et al., 2002), and heat treatment has been shown to reduce probiotics adhesion
abilities (Ouwehand et al., 2000). Many studies have shown these adhesion properties of
the probiotic strains used in this study, concluding that GG binds very well to intestinal
epithelia and mucus (Kirjavainen et al., 1998; Ouwehand et al., 1999; Kankaanpää et al.,
2000; Ouwehand et al., 2000; Morita et al., 2002), and LC-705  and JS show lower
binding abilities (Tuomola et al., 2000; Ouwehand 2002). Furthermore, previous AFB1
binding by probiotics (L. rhamnosus GG and L. casei) have been found to reduce
subsequent binding to intestinal cell lines Caco-2 and HT-29 (Kankaanpää et al., 2000;
Hwang et al., 2005), suggesting that probiotic adhesion and AFB1 binding interfere with
each other.
Based on these findings, we hypothesized that intestinal mucus, bound to the surface
of probiotic bacteria, might impact on the subsequent AFB1 binding capacity of these
probiotics. We therefore adapted the in vitro AFB1 binding assays to include intestinal
mucus. As a first step, we assessed the mucus binding ability of GG and the probiotic
mixture LC-705+JS and found that the LC-705+JS removes a smaller amount of mucus as
compared to GG, which is in agreement with findings from the adhesion studies.
Intestinal mucus was clearly bound rather than degraded by probiotics, since large portions
of the bound mucus could be recovered from the bacterial surface by aqueous washing
(67% for GG and 31% for LC-705+JS, II) and both Lactobacilli and Propionibacteria
have appeared unable to degrade intestinal mucus (Ruseler-van Embden et al., 1995;
Ouwehand et al., 2002). We also found that probiotic mucus binding reduced subsequent
binding of AFB1 by GG and LC-705+JS, and vice versa. These findings would suggest
direct competition of mucus and AFB1 for bacterial binding sites, but different bacterial
surface components are responsible for mucus binding (Rojas et al., 2002) and AFB1
binding (Tuomola et al., 2000; Lahtinen et al., 2004). Furthermore, heat treatment of
probiotics, known to interfere with protein structures on the bacterial surfaces, has been
found to reduce mucus binding (Ouwehand et al., 2000) but at the same time increase
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probiotic AFB1 binding (El-Nezami et al., 1998b). Therefore, the two processes must
hinder each other through a different mechanism, e.g. steric hindrance.
The effect of intestinal mucus on bacterial AFB1 binding was further illustrated by
comparing the AFB1 binding ability of LC-705+JS observed ex vivo in the chick duodenal
loops with results from the in vitro assay including intestinal mucus (I). From in vitro
experiments, we selected the bacterial number sufficiently large to bind around 60% of the
AFB1 dose. In the presence of intestinal mucus, this was significantly reduced to around
30% AFB1 binding, but still remained above the values obtained from the ex vivo study (I).
This implies that the situation in the intestinal tract of the animal is more complex than can
be explained with intestinal mucus and other factors may influence AFB1 binding.
Strain-specific interference of intestinal mucus with probiotic AFB1 binding clearly
shows the necessity of intestinal mucus to be incorporated into screening assays, aiming at
characterizing new candidate probiotics for AFB1 removal. From studies I and II, we
concluded that the LC705+JS mix showing poor AFB1 binding results in vitro in the
presence of intestinal mucus, should not be further used. Consequently, all experiments
conducted thereafter (III and IV) were carried out using GG.
6.2 Impact of probiotic AFB1 binding on absorption and toxicity of AFB1
 in rats in vivo (III)
Fecal excretion of AFB1
Under in vivo conditions, one would expect probiotic bacteria to bind AFB1 as soon as
they interact with each other inside the intestinal tract. Thereafter bacteria should travel
through the intestinal tube and be excreted eventually into feces, taking bound AFB1 with
them. Consequently, fecal levels of AFB1 should allow us to estimate AFB1 binding
occurring in vivo, even though a percentage of binding calculated from results obtained
from rat fecal samples lies well below results in vitro or ex vivo. Assessing AFB1 levels in
the fecal sample is difficult and extracting and purifying aflatoxins to an extent that is
suitable for further HPLC analysis lead to a poor recovery of AFB1 from the fecal
material. As a result, animal studies on fecal excretion of aflatoxins have used radio-
labeled aflatoxin and then measured total excretion of radioactivity in the feces (Coulombe
and Sharma, 1985; Hsieh and Wong, 1994). This method however, is not suitable to
differentiate between dietary, unabsorbed fecal AFB1, and hepatic metabolites, then
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excreted into the intestinal lumen via the biliary route. A pilot clinical trial conducted in
Egypt (El-Nezami et al., 2000a) managed to assess the impact of probiotic
supplementation on fecal AFB1 excretion, but showed a reduction in fecal AFB1 level in
the presence of probiotics rather than the expected increase. The authors concluded that
sample timing was the cause of this effect, since fecal samples were taken one week after
starting a daily probiotic intervention. This is in agreement with our in vivo findings,
suggesting that probiotic administration only increased fecal excretion of AFB1 within 24
hours of AFB1 dosage, but not at later time points. However, the ultimate goal is to reduce
AFB1 bioavailability in the intestinal tract, and an increase in fecal AFB1 excretion in the
presence of probiotics at any time point is convincing evidence that this goal can be
achieved.
One of the main shortcomings of this in vivo trial was administration of both AFB1
and probiotics via oral gavage. Even though a simple and precise technique, it does not
allow any conclusion on probiotic AFB1 binding capacity from contaminated foodstuffs
which would be the natural route of exposure.
AFB1 absorption
There are two widely used methods to assess AFB1 absorption and exposure in
animals and humans. First is to look at the blood circulation of the stable AFB1-albumin
adduct (Sabbioni et al., 1987; Hsieh and Wong, 1994; Vinitketkumnuen et al., 1999;
Turner et al., 2005) and second is to measure the excretion of metabolites in urine, such as
AFM1 and AFB1-N7-guanine (Wogan et al., 1967; Kumagai, 1989; Hsieh and Wong,
1994; Hoogenboom et al., 2001; Walton et al., 2001). In our study (III), the plasma levels
of AFB1-albumin adduct were only slightly, but not significantly reduced in rats dosed
with probiotic GG. Since the plasma AFB1-albumin adduct has a half-life in rats of only
several days (Sabbioni et al., 1987; Vinitketkumnuen et al., 1999), some of the circulating
adduct had likely been degraded by the time we measured the AFB1 albumin adduct levels
(3 days after dosing). Additionally, we have measured the urinary levels of AFM1 and this
did not differ in rats treated either with or without GG.
Findings from the AFB1-albumin adduct and the urinary AFM1 levels may reflect a
saturation of the hepatic metabolizing capacity within the dosing regime used (high, toxic,
single dose of AFB1). Both biomarkers aim at low detection limits and precise
measurements of low aflatoxin levels. However, in a study with dietary levels of AFB1,
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they would be useful biomarkers to assess changes in AFB1 absorption due to probiotics
administration.
Formation of AFM1 and AFL
Besides the binding and absorption, we also investigated the effect of probiotic
bacteria on intestinal metabolism and AFB1 toxicity in rat. Few studies have addressed the
role and importance of the intestinal tract in AFB1 metabolism. Pharmacokinetic studies in
rats have identified conjugated metabolites such as AFB1-glutathione and AFP1-
glucuronidate as major fecal metabolites, and these are clearly excreted into the intestinal
lumen via the bile (Hsieh and Wong, 1994). These studies also show that no, or only a
very small portion (0.3%) of administered radioactivity can be detected in the chloroform
extractable fraction of the rat bile 24 hours after dosing, which would contain free
hydroxylated AFB1 metabolites such as AFM1 or AFL (Hsieh and Wong, 1994; Degen
and Neumann, 1978). These findings suggest that the free aflatoxins found in feces in the
present study (4.9 % of the dose, 24 hours after dosing) represent mostly unabsorbed
aflatoxin, and possibly some conjugated biliary aflatoxin metabolites that have
subsequently been deconjugated by colonic microbiota (Wei et al., 1981). Increased
excretion of AFM1 in the presence of probiotics seems to contradict the expected effect of
reduced AFB1 uptake and hepatic metabolism. Formation of AFM1 inside the intestinal
lumen by microbes can be eliminated, since rat cecal microflora, ruminal microbiota and
probiotic bacteria are not able to metabolize AFB1 to AFM1 (Wei et al., 1981; Coulombe
and Sharma, 1985). However, it can be envisaged that AFB1 may be metabolized to AFM1
within the enterocytes of the gastrointestinal system, which expresses CYP 1A2, (Ding
and Kaminsky, 2003; Lindell et al., 2003) and that some of these metabolites could diffuse
back into the gut lumen. If the gut lumen additionally contains probiotics, re-uptake of
AFM1 by intestinal epithelia may be restricted and the probiotic bound AFM1 would be
excreted via the feces. GG  is known to bind AFM1 equally efficiently as AFB1 (Pierides
et al., 2000; Kabak and Var, 2004), and thus removal of this major toxic metabolite could
contribute to the overall increased clearance of aflatoxins from the rat. These data
therefore imply that intestinal metabolism of AFB1 is an important process in the
toxicokinetics of AFB1 and that probiotic bacteria impact upon these processes. However,
a recent human study failed to show an impact of probiotics on fecal excretion of any of
these metabolites (unpublished data), and further work is needed to fully understand the
role of the intestinal epithelium on aflatoxin metabolism.
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AFB1 toxicity
Liver is the main target organ for AFB1 toxicity and liver-specific enzyme activities in
plasma have often been used as toxicity marker. The levels of ALT activity in the control
animals and the elevation after the AFB1 dosing in the present study (III) are comparable
to values reported in the literature for Wistar rats at a similar AFB1 dose (Lu and Li,
2002). In another study, using Fischer 344 rats, a much stronger elevation in ALT activity
due to aflatoxin treatment was observed, confirming the strain specific difference in
susceptibility to AFB1 (Maxuitenko et al., 1997). In our study, we observed slightly
elevated ALT activity in rat plasma of the AFB1 group (149% increase compared to
untreated controls, p=0.053), which was significantly associated with AFB1-albumin
levels, a marker of aflatoxin intake and hepatic metabolism. In rats treated with GG prior
to AFB1, the levels of ALT activity were more similar to controls and were reduced by
46 % compared to the AFB1 only group, though the difference did not reach statistical
significance (p=0.171). These findings suggest that the probiotic treatment may reduce
hepatotoxic effects of a high dose of AFB1 in rats, though high individual variation in liver
function and low number of animals may have reduced the power of the study.
Feed intake and body weight gain in rats are reduced by AFB1 in a dose dependent
manner at doses ranging from 0.25 to 3 mg/kg body weight (Maxuitenko et al., 1997). In
our study, reduction of body weight gain after a single high dose of AFB1 was more
pronounced in rats receiving AFB1 only than in animals receiving the probiotic dose
additional to AFB1. Probiotic bacteria alone had no effect on body weight gain suggesting
that the effect is related to probiotics reducing the amount of free AFB1 within the
intestinal tract, and thus lowering toxicity. In children naturally exposed to aflatoxins
through diet, aflatoxin biomarker levels have been associated with growth faltering (Gong
et al., 2002; Gong et al., 2003; Turner et al., 2003), and one hypothesis is that aflatoxin
induced intestinal damage is the cause of this faltering. Since probiotic bacteria may also
enhance intestinal barrier integrity (Parvez et al., 2006) they may indirectly protect the
intestinal epithelium against AFB1 toxicity.
In conclusion, in vivo data suggest that by increasing the excretion of orally dosed
aflatoxin via the fecal route, probiotic treatment prevents weight loss and may reduce
hepatotoxic effects caused by a high dose of AFB1. However, further studies administering
AFB1 repeatedly, mixed into feed and at naturally occurring levels are needed before we
fully understand the potential of probiotics to reduce absorption of AFB1 for future use in
combating human AFB1 exposure.
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6.3 Impact of probiotic binding on AFB1 uptake and toxicity in Caco-2
 cells (IV)
The intestinal cell line Caco-2 has been used in mycotoxin absorption studies (Caloni
et al., 2002; Mata et al., 2004; Versantvoort et al., 2005; Caloni et al., 2006) as well as in
probiotic adhesion studies (El-Nezami et al., 2000a) in the past and has proven a useful
tool to reduce the use of experimental animals. In this part of the study we therefore aimed
at adapting the Caco-2 cell model for our probiotic AFB1 binding studies, to further assess
the impact of probiotic AFB1 binding on its transport, intestinal metabolism and intestinal
toxicity. Two compartment cell culture dishes were used to allow measurements of AFB1
transport through the intestinal epithelium and epithelial barrier function. Adjusting the
model for AFB1 binding studies appeared to be difficult, since much larger numbers of
bacteria are needed (1-10x1010 CFU/ml) as compared to probiotic adhesion studies
(107–108 CFU/ml) (Kirjavainen et al., 1998; Ouwehand et al., 1999; Kankaanpää et al.,
2000; Ouwehand et al., 2000; Morita et al., 2002). For this reason, only non-viable
bacteria could be used in the present study, since viable bacteria of this number would be
metabolically active in the cell culture medium, producing metabolites e.g. lactic acid that
would significantly affect the Caco-2 cells viability (unpublished data). However, heat
treatment of bacteria reduces their adhesion properties to intestinal surfaces (Ouwehand et
al., 2000), and therefore might disable the positive probiotic effect in a host’s intestinal
tract.
AFB1 binding in cell culture medium was not different from binding in PBS, and
could easily be measured by HPLC. The advantage of the two compartment model is that
the effect of tissue uptake on binding can be taken into account, although transport of
AFB1 by Caco-2 cells (92% of dose in apical chamber after 30 min) is clearly slower than
by the intestinal epithelium (4% of dose in lumen of chicks after 30 min).
From this Caco-2 transport model, permeability coefficients can be easily calculated
by comparing AFB1 levels in apical and basolateral chambers. Permeability coefficients
(Pe) appear to increase with increasing AFB1 concentrations added, leading to a Pe of
9x10-6 cm/sec at 16 nM (Versantvoort et al., 2005), 18x10-6 cm/sec at 1µM (Mata et al.,
2004) and 25x10-6 cm/sec at 160 µM (III). Passive diffusion has been suggested as the
mechanism of AFB1 absorption, since transport in both directions, apical to basolateral and
basolateral to apical, occurred at similar rates (Mata et al., 2004). In the presence of GG,
the Pe was decreased dramatically, suggesting a reduction in AFB1 transport through the
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intestinal monolayer. Calculating Pe from the Caco-2 transport model makes it easy to
assess transport and to compare results between different studies.
Formation of AFM1 and AFL
The hypothesis of intestinal epithelia cells metabolizing AFB1, suggested from our in
vivo results, is further supported by Caco-2 data, showing that intestinal cells are capable
of producing AFM1 and AFL from AFB1.  Our results also suggest that the presence of
GG (heat-killed though) might even increase the formation of the AFM1, since increased
amount of AFM1 were found in both chambers of the transport model. These data certainly
need further investigation, clarifying the possible impact of GG on the activity of
cytochrome enzymes, responsible for AFM1 formation. However, AFL formation, known
to occur spontaneously under reducing anaerobic conditions or facilitated by cytosolic
reductases (Eaton et al., 1994), was clearly reduced in the presence of GG.
Intestinal toxicity of AFB1
To exert toxic effects, aflatoxin B1 has to be activated to the highly reactive AFB1-
8,9-epoxide (Eaton et al., 1994; Massey et al., 1995), which then adducts to proteins and
DNA. Caco-2 cells lack the expression of CYP 3A, the key enzyme to facilitate this
activation, and 1,25(OH)2D3 has to be used to induce the expression of this enzyme. A
decrease in the transepithelial resistance is linked to toxic effects via damaging tight
junctions between epithelial cells and therefore disrupting the intestinal barrier function. In
our study, we found that a high concentration of AFB1 (150 ?M) reduced TER readings
significantly in 1,25(OH)2D3 induced Caco-2 cells without causing gross toxicity. By
adding probiotic bacteria this negative effect was attenuated.
Furthermore, we observed significant DNA damage after incubating 1,25(OH)2D3
induced Caco-2 with a high dose of AFB1. Only when severe DNA damage occurred, the
presence of probiotic bacteria reduced the DNA damage significantly. Compared to
studies in vitro in rat epithelia (Watzl et al., 1999) and in a liver cell line Hep G2 (Uhl et
al., 2000), AFB1 induced DNA damage in our study was very low, and required a high
AFB1 dose and long incubation time. These findings suggest that induction of the AFB1
bioactivation was not sufficient to reach CYP 3A levels observed in vivo.
Our data clearly demonstrate that GG was able to reduce AFB1 transport, formation of
AFL and DNA damage. However, the use of this cell culture model to study effect of
probiotic aflatoxin binding has major limitations because AFB1 has to be applied in a high
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concentration and for a long time (up to 72 hours) for formation of AFB1 metabolites and
damage of DNA in Caco-2 cells to occur. The metabolically modified Caco-2/TC-7 clone
(Sambuy et al., 2005), expressing higher levels of CYP 3A enzyme, could be an
alternative to further apply this model for probiotic AFB1 binding studies.
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7  Conclusions and future aspects
These studies were conducted to investigate whether probiotic bacteria bind AFB1
under physiological conditions in the gut and whether such binding results in a reduction
of AFB1 bioavailability and toxicity. The probiotics used were Lactobacillus rhamnosus
strain GG (GG) and a mixture of Lactobacillus rhamnosus LC-705 and Propionibacterium
freudenreichii ssp. shermanii JS (LC-705+JS). From the series of experiments conducted,
the following conclusions can be drawn:
· Both probiotic preparations were able to bind AFB1 in vitro, but in the intestinal
loops of chicks, the probiotic mixture LC705+JS performed less well than
anticipated from in vitro results.
· Intestinal mucus was identified as one factor that could influence AFB1 binding by
bacteria in a strain specific way, and should therefore be included in in vitro
screening assays for new probiotic candidate strains.
· Probiotic GG administration slightly reduced toxic effects of AFB1 in liver and
prevented body weight loss of rats via binding AFB1 in the intestinal lumen and
increasing its excretion in feces.
· A high concentration of AFB1 was found to be toxic to intestinal cells in a Caco-2
model, and transport and toxic effects were reduced by GG binding of the AFB1
added.
In summary these results show that probiotics, and here especially GG, are able to
bind AFB1 under in vivo conditions. However, quantitative assessment of this binding
from intestinal content and feces is difficult. The percentages of AFB1 binding in these
biological samples are naturally much below the values obtained from in vitro
experiments, but nevertheless positive effects of probiotic administration were obvious in
rats and intestinal cells.
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Nevertheless, this series of studies has opened a range of questions, which need to be
addressed in future work. The administration of aflatoxin and probiotic bacteria in normal
food matrix has to be taken into account, since we do not know whether aflatoxin in
naturally contaminated crops is accessible for probiotic binding. These bioaccessibility
studies could be conducted using the Caco-2 TC-7 cell model. Furthermore, an animal
feeding trial needs to be conducted with levels of AFB1 naturally present in food or feed,
to assess effects of probiotics on levels of biomarkers of exposure rather than toxic
endpoints, as were used in the present study. This would allow a better prediction of
changes to be expected in a human population naturally exposed to dietary aflatoxins. The
ultimate goal of this work is to reduce human exposure to aflatoxin and to other harmful
food components using probiotic bacteria. This might, in combination with other pre- and
post harvest intervention into AFB1 contamination of food, help to prevent human
exposure to aflatoxins and make food more safe.
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